Benzodiazepine derivatives for the treatment of respiratory syncytial virus (RSV) infection
By developing novel benzodiazepine derivatives, particularly benzodiazepine pyrazole compounds of formula (I), the shortcomings of existing anti-RSV treatments have been addressed, providing effective inhibition of RSV and favorable pharmacokinetic properties, making them suitable for the treatment of RSV infection in a wide range of populations.
Patent Information
- Application Number
- CN202080082952.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-10-22
- Filing Date
- 2020-10-22
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2040-10-22
AI Technical Summary
Existing anti-RSV treatments are limited, especially for non-premature infants and high-risk infants, where there is a lack of effective treatment options. Furthermore, existing small molecule inhibitors have shortcomings in terms of pharmacokinetic properties.
A series of novel benzodiazepine derivatives, specifically benzodiazepine pyrazole compounds of formula (I), have been developed, exhibiting effective anti-RSV activity and favorable pharmacokinetic properties, and are suitable for the treatment or prevention of RSV infection.
These compounds exhibit significant inhibitory effects on RSV and possess good bioavailability and solubility, providing an effective treatment and prevention method for RSV infection, suitable for individuals of different ages and immune statuses.
Smart Images

Figure CN114761397B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to benzodiazepines Derivatives and their use in treating or preventing respiratory syncytial virus (RSV) infection. Background Art
[0002] RSV is a negative-sense single-stranded RNA virus of the family Paramyxoviridae. RSV is easily spread by the secretions of the infected person via surface or hand-to-hand transfer. Unlike influenza, it is not spread by small particle aerosols. After successful inoculation, the incubation period is 4 to 6 days, during which the virus spreads from the nasopharynx to the lower respiratory tract by fusion of infected cells with uninfected cells and shedding of necrotic epithelium. In infants, combined with increased mucus secretion and edema, this can lead to mucus blockage, causing overexpansion and collapse of distal lung tissue, indicating bronchiolitis. Common hypoxia, and usually impaired feeding ability due to respiratory distress. In RSV pneumonia, the inflammatory infiltration of the airways is composed of mononuclear cells and is more generalized to involve bronchioles, bronchi and alveoli. It has been found that the duration and degree of viral shedding are related to the clinical symptoms and severity of the disease.
[0003] RSV is the leading cause of severe respiratory infection in infants and young children worldwide. Morbidity and mortality are highest in premature infants and infants with chronic lung or heart disease, although many infants hospitalized with RSV infection are otherwise healthy. Severe RSV infection in infancy can lead to recurrent wheezing for years and is associated with the development of asthma later in life.
[0004] RSV is also a major cause of morbidity and mortality in elderly and immunocompromised children and adults, as well as patients with chronic obstructive pulmonary disease (COPD) and congestive heart failure (CHF).
[0005] RSV has a seasonal onset; it is highly predictable and occurs in the winter in both hemispheres, from September to May in Europe and North America, peaking in December and January, and can occur year-round in tropical countries. It affects >90% of infants and young children < 2 years of age, and because natural immunity is short-lived; many will be reinfected each year. Like influenza, in the elderly, RSV causes about 10% of winter hospitalizations and has an associated mortality rate of 10%.
[0006] Current anti-RSV treatment includes the use of an anti-RSV monoclonal antibody, called palivizumab. This use of palivizumab is a preventive rather than therapeutic treatment of RSV. Although this antibody is generally effective, its use is limited to premature infants and high-risk infants. In fact, its limited availability means that it is unavailable for many people who need anti-RSV treatment. Therefore, there is an urgent need for an effective alternative to existing anti-RSV treatment.
[0007] Small molecules have also been proposed as inhibitors of RSV. These include benzimidazoles and benzodiazepines For example, RSV604, a benzodiazepine with submicromolar anti-RSV activity The discovery and initial development of the compound is described in Antimicrobial Agents and Chemotherapy, September 2007, 3346-3353 (Chapman et al). Benzodiazepines for RSV Inhibitors are also disclosed in publications including WO2004 / 026843 and WO2005 / 089770 (Arrow Therapeutics Limited); WO2016 / 166546 and WO2018 / 033714 (Durham University); and WO2017 / 015449, WO2018 / 129287 and WO2018 / 226801 (Enanta Pharmaceuticals, Inc.).
[0008] There is a need to identify further compounds having anti-RSV activity, particularly compounds having a combination of potent antiviral activity and favorable pharmacokinetic properties. Summary of the invention
[0009] A series of new benzodiazepines have been discovered The derivatives have effective anti-RSV activity as well as favorable pharmacokinetics and good solubility. Therefore, the present invention provides a compound, which is a benzodiazepine of formula (I) Pyrazole:
[0010]
[0011] in:
[0012] R 1 and R 2 Each of is independently H or halogen;
[0013] R 3 H, C1-C6 alkyl, -NHR 8 or-OR';
[0014] (i) and are keys, and and does not exist; or and are keys, and and does not exist;
[0015] R 4 is H or a group selected from C1-C6 alkyl, C3-C6 cycloalkyl and 4- to 10-membered heterocyclyl, which group is unsubstituted or substituted;
[0016] R 5 is H or halogen;
[0017] R 6 Yes-OR 8 、-NR 8 R 9 or -R 8 ;
[0018] R 7 is H or halogen;
[0019] R 8 and R 9 Each of the groups is independently H or a group selected from C1-C6 alkyl, C3-C6 cycloalkyl and 4- to 10-membered heterocyclyl, which group is unsubstituted or substituted;
[0020] R' is H or C1-C6 alkyl; and
[0021] One of V and W is CH, and the other is CH or N;
[0022] or a pharmaceutically acceptable salt thereof. DETAILED DESCRIPTION
[0023] When any group, ring, substituent or moiety as defined herein is substituted, it is typically substituted by Q as defined below.
[0024] C 1-6 The alkyl group or moiety is straight chain or branched. 1-6 Alkyl groups are usually C 1-4 Alkyl or C 4-6 Alkyl. C 1-6 Examples of alkyl and moieties include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl (i.e. 3-methylbutan-1-yl), tert-pentyl (i.e. 2-methylbutan-2-yl), neopentyl (i.e. 2,2-dimethylpropan-1-yl), n-hexyl, isohexyl (i.e. 4-methylpentan-1-yl), tert-hexyl (i.e. 3-methylpentan-3-yl) and neopentyl (i.e. 3,3-dimethylbutan-1-yl). For the avoidance of doubt, when two alkyl moieties are present in a group, the alkyl moieties may be the same or different. C 1-6 Alkyl is unsubstituted or generally substituted by one or more groups Q as defined below. For example, C 1-6Alkyl is unsubstituted or substituted by 1, 2 or 3 groups Q as defined below.
[0025] Q is halogen, nitro, -CN, OH, C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, C 1-6 Alkylthio, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-4 Haloalkoxy, -CO2R', -NR'2, -SR', -S(=O)R', -S(=O)2R', C3-C 10 cycloalkyl, 5- to 10-membered heterocyclyl, 5- to 12-membered aryl, or 5- to 10-membered heteroaryl, wherein each R' is independently selected from H, C 1-6 Alkyl, C 3-10 Cycloalkyl, 5- to 10-membered heterocyclic group, C6-C 10 Aryl and 5- to 10-membered heteroaryl. For the avoidance of doubt, the alkyl, alkoxy, alkylthio, cycloalkyl, heterocyclyl, aryl and heteroaryl portions of these definitions are themselves typically unsubstituted.
[0026] C 1-6 The alkoxy group is straight chain or branched. 1-4 Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, n-propoxy, n-butoxy, sec-butoxy or tert-butoxy. 1-6 Alkoxy is unsubstituted or typically substituted by one or more groups Q as defined above.
[0027] C 1-6 The alkylthio group is straight chain or branched. 1-4 Alkylthio, for example methylthio, ethylthio, propylthio, isopropylthio, n-propylthio, n-butylthio, sec-butylthio or tert-butylthio. 1-6 Alkylthio is unsubstituted or substituted - typically by one or more groups Q as defined above.
[0028] Halogen or halo group is F, Cl, Br or I. Typically, it is F or Cl. 1-6 Alkyl groups can be represented by "C 1-6 "Haloalkyl" means a C group as defined above in which one or more hydrogen atoms are replaced by halogen. 1-6 Similarly, halogen-substituted C 1-6 Alkoxy can be represented by "C 1-6 "Haloalkoxy" means a C as defined above in which one or more hydrogen atoms are replaced by halogen. 1-6 Alkoxy. Generally, C 1-6 Haloalkyl or C 1-6The haloalkoxy group is substituted by 1, 2 or 3 of said halogen atoms. The haloalkyl and haloalkoxy groups include perhaloalkyl and perhaloalkoxy groups, such as -CX3 and -OCX3, wherein X is a halogen, such as -CF3, -CCl3, -OCF3 and -OCCl3.
[0029] C 1-6 Hydroxyalkyl is a C alkyl group as defined above substituted with one or more OH groups. 1-6 Alkyl. Typically, it is substituted with one, two or three OH groups. Preferably, it is substituted with a single OH group.
[0030] C6-C 10 Aryl is an aromatic carbocyclic group containing 6 to 10 carbon atoms. It is a monocyclic or fused bicyclic ring system in which an aromatic ring is fused to another aromatic carbocyclic ring. 10 Examples of aryl groups include phenyl and naphthyl. When substituted, aryl groups are generally substituted by a group Q as defined above, for example by 1, 2 or 3 groups selected from the group Q as defined above. More specifically, substituted aryl groups such as substituted phenyl groups are selected from C1-C6 alkyl, halogen, -OR 8 and -N(R 8 )2 is substituted with 1 or 2 groups, wherein R 8 is H or C1-C6 alkyl, when there are two, each R 8 Same or different.
[0031] C 3-10 Cycloalkyl is a saturated hydrocarbon ring having 3 to 10 carbon atoms. 3-10 Cycloalkyl can be, for example, a C3-C7 cycloalkyl, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl. Typically, it is a C3-C6 cycloalkyl, or a C4-C6 cycloalkyl, such as cyclobutyl, cyclopentyl or cyclohexyl. In one embodiment, it is a cyclobutyl. 3-10 Cycloalkyl is unsubstituted or typically substituted by one or more groups Q as defined above.
[0032] The 4- to 10-membered heteroaryl or moiety is a 4- to 10-membered aromatic heterocyclic group containing 1, 2, 3 or 4 heteroatoms selected from O, N and S. It is monocyclic or bicyclic. Typically, it contains 1 N atom and 0, 1, 2 or 3 additional heteroatoms selected from O, S and N. It can be, for example, a monocyclic 5- to 7-membered heteroaryl, such as a 5- or 6-membered N-containing heteroaryl. Examples include pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, furanyl, thienyl, pyrazolidinyl, pyrrolyl, Oxazolyl, Azolyl, iso 1-10 yuan. Examples include quinolyl, isoquinolyl, quinazolyl, quinoxalinyl, indolyl, isoindolyl, indazolyl, imidazolyl, pyrrolopyridinyl, pyrazolopyrimidinyl and pyrrolopyrimidinyl. When substituted, the heteroaryl (monocyclic or bicyclic) is generally replaced by one or more, for example 1, 2 or 3, selected from C 1-4 The alkyl group and the group Q are substituted with the groups defined above.
[0033] A 4- to 10-membered heterocyclyl is a monocyclic or bicyclic non-aromatic saturated or unsaturated ring system containing 5 to 10 carbon atoms and at least one atom or group selected from N, O, S, SO, SO2 and CO (more generally N or O). When the ring system is bicyclic, one ring may be saturated and one ring may be unsaturated. Generally, it is C 4-10 A ring system in which 1, 2 or 3 carbon atoms in the ring are substituted by atoms or groups selected from O, S, SO2, CO and NH. More generally, it is a monocyclic ring, preferably a monocyclic C4-C6 ring. Examples include piperidinyl, piperidine-2,6-dione, piperidine-2-one, piperazinyl, morpholinyl, thiomorpholinyl, S,S-dioxothiomorpholinyl, 1,3-dioxolanyl, pyrrolidinyl, imidazol-2-one, pyrrolidin-2-one, oxetanyl, tetrahydrofuranyl and tetrahydropyranyl moieties.
[0034] For the avoidance of doubt, although the above definitions of heteroaryl and heterocyclyl refer to "N" atoms which may be present in the ring, it will be apparent to the skilled chemist that any such N atom will be protonated (or will carry a substituent as defined above) if it is attached to its adjacent ring atoms by a single bond. Such protonated forms are included within the present definitions of heteroaryl and heterocyclyl.
[0035] In one embodiment of formula (I) as defined above, R 2 Benzodiazepines A halogen substituent at the 9-position of the base ring system, specifically F. Examples of such compounds are those of the following formula (I'):
[0036]
[0037] Where R 1 is H or halogen, R 2 is H or halogen, and the remaining groups and variables are as defined above for formula (I). 1 is H or F, and R 2 is H or F. For example, R 1 is H or F, and R2 It's F.
[0038] In one embodiment of formula (I), and are keys, and and This compound has the following formula (Ia):
[0039]
[0040] wherein all groups and variables are as defined above for formula (I) or (I').
[0041] In another embodiment of formula (I), and are keys, and and This compound has the following formula (Ib):
[0042]
[0043] wherein all groups and variables are as defined above for formula (I) or (I').
[0044] In one embodiment of the above formulae (I), (I'), (Ia) and (Ib), V is N and W is CH. Examples of such structures include benzodiazepines of the following formulae (Ia') and (Ib'): Pyrazole:
[0045]
[0046]
[0047] In formula (Ia') and (Ib'), R 1 To R 7 Each of is as defined above for formula (I) or (I').
[0048] In another embodiment of the above formulae (I), (I'), (Ia) and (Ib), V is CH and W is N. Examples of such structures include benzodiazepines of the following formulae (Ia") and (Ib") Pyrazole:
[0049]
[0050] In formula (Ia") and (Ib"), R 1 To R 7 Each of is as defined above for formula (I) or (I').
[0051] In further embodiments of the above formulae (I), (I'), (Ia) and (Ib), V is CH and W is CH. Examples of such structures include benzodiazepines of the following formulae (Ia'") and (Ib'") Pyrazole:
[0052]
[0053] In formula (Ia'") and (Ib'"), R 1 To R 7 Each of is as defined above for formula (I) or (I').
[0054] In the compounds of the present invention having any of the above defined structural formulas, R 5 It can be bonded at any available ring position of the six-membered ring to which it is attached. In one embodiment, it is bonded at ring position 2, i.e., ortho to the bond connecting the six-membered ring to the adjacent pyrazole ring. In general, R 5 The 2-position of is F, i.e., a 2-fluoro group.
[0055] In the compounds of the present invention having any of the above defined structural formulas, R 6 It may be bonded at any available ring position of the six-membered ring to which it is attached. In one embodiment, it is bonded at ring position 4, i.e. para to the bond connecting the six-membered ring to the adjacent pyrazole ring.
[0056] In one aspect, the present invention provides a compound which is a benzodiazepine of formula (I") Pyrazole:
[0057]
[0058] wherein each of the groups and variables are as defined above for formula (I), or a pharmaceutically acceptable salt thereof.
[0059] When R in formula (I") 1 and R 2 When the same ring positions as shown in the above formula (I') are occupied, the resulting compound is a benzodiazepine of the following formula (I''): Pyrazole:
[0060]
[0061] Where R 1 is H or halogen, R 2 is H or halogen, and the remaining groups and variables are as defined above for formula (I). 1 is H or F, and R 2 is H or F. For example, R 1 is H, and R2 It's F.
[0062] In one embodiment of the compounds of the present invention having any of the structural formulas (I"), (Ia), (Ib), (Ia'), (Ib'), (Ia"), (Ib"), (Ia'") or (Ib'") as defined above, R 2 In benzodiazepines In this embodiment, typically, R 2 is a halogen substituent, specifically F. More generally, in this embodiment, R 1 is H or F, and R 2 is H or F. For example, R 1 is H or F, and R 2 It's F.
[0063] In the compounds of the present invention having any of the above defined structural formulas, R 3 is selected from H, C1-C6 alkyl, -NR 8 R 9 and -OR', wherein R' is H or a C1-C6 alkyl group, such as methyl or ethyl, and R 8 and R 9 Each of the above-defined structural formulas is independently H or a group selected from C1-C6 alkyl, C3-C6 cycloalkyl and 4- to 10-membered heterocyclic groups, which is unsubstituted or substituted. 3 is selected from H, C1-C6 alkyl and -NR 8 R 9 Generally, R 8 is H, and R 9 is H or a group selected from C1-C6 alkyl, C3-C6 cycloalkyl and 4- to 10-membered heterocyclic group, which group is unsubstituted or substituted. 8 is H, and R 9 It is H or C1-C6 alkyl.
[0064] In the compounds of the present invention having any of the above defined structural formulas, R 4 is H or a group selected from C1-C6 alkyl, C3-C6 cycloalkyl and 4- to 10-membered heterocyclic group, which group is unsubstituted or substituted. 4 It is a group selected from C1-C6 alkyl (such as C1-C3 alkyl), C3-C6 cycloalkyl (such as cyclopropyl) and 4- to 10-membered heterocyclic groups (for example, O-containing heterocyclic groups such as oxetanyl, tetrahydrofuranyl or tetrahydropyranyl).
[0065] In the compounds of the present invention having any of the above defined structural formulas, R5 is H or a halogen, specifically F.
[0066] In the compounds of the present invention having any of the above defined structural formulas, R 6 Yes-OR 8 、-NR 8 R 9 or -R 8 , where R 8 and R 9 Each of R is H or a group selected from C1-C6 alkyl, C3-C6 cycloalkyl and 4- to 10-membered heterocyclic group, which group is unsubstituted or substituted. 6 Select from -OR 8 、-NR 8 R 9 and R 8 , where R 8 is C1-C6 alkyl (such as C1-C3 alkyl), C3-C6 cycloalkyl (such as cyclopropyl or cyclobutyl), and R 9 is H or C1-C6 alkyl, the alkyl and cycloalkyl being unsubstituted or substituted. More generally, R 6 Yes-OR 8 、-NR 8 R 9 or R 8 , for example -OR 8 or -NR 8 R 9 , where R 8 is an unsubstituted C1-C6 alkyl group (such as methyl, ethyl or isopropyl) or a C3-C6 cycloalkyl group (such as cyclopropyl or cyclobutyl), the cycloalkyl group is unsubstituted or substituted by an unsubstituted C1-C3 alkyl group (such as methyl), and R 9 is C1-C6 alkyl or H.
[0067] Specific compounds of the present invention include the following:
[0068] 1-Ethyl-5-[2-fluoro-6-(methylamino)pyridin-3-yl]-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide;
[0069] 1-Ethyl-5-[6-(ethylamino)-2-fluoropyridin-3-yl]-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide;
[0070] 1-Ethyl-5-[2-fluoro-6-(propan-2-ylamino)pyridin-3-yl]-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide;
[0071] 1-Ethyl-5-[2-fluoro-6-(cyclopropylamino)pyridin-3-yl]-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide;
[0072] 5-[6-(Cyclobutylamino)-2-fluoropyridin-3-yl]-1-ethyl-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide;
[0073] 1-Ethyl-5-[2-fluoro-6-[(1-methylcyclopropyl)amino]pyridin-3-yl]-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide;
[0074] 5-[5-(Cyclopropylamino)-3-fluoropyridin-2-yl]-1-ethyl-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide;
[0075] 1-Ethyl-5-[3-fluoro-5-(propan-2-ylamino)pyridin-2-yl]-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide;
[0076] 1-Ethyl-5-[2-fluoro-4-(propan-2-ylamino)phenyl]-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide;
[0077] 1-ethyl-5-[6-(ethylamino)-2-fluoropyridin-3-yl]-3-methyl-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide;
[0078] 5-[6-(Cyclopropylamino)-2-fluoropyridin-3-yl]-1-ethyl-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide;
[0079] 5-[5-(Cyclopropylamino)-3-fluoropyridin-2-yl]-1-ethyl-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide;
[0080] 1-Ethyl-5-[5-(ethylamino)-3-fluoropyridin-2-yl]-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide;
[0081] 1-Cyclopropyl-5-[6-(ethylamino)-2-fluoropyridin-3-yl]-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide;
[0082] 1-Cyclopropyl-5-[6-(cyclopropylamino)-2-fluoropyridin-3-yl]-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide;
[0083] 5-[6-(Cyclopropylamino)-2-fluoropyridin-3-yl]-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-1-propan-2-ylpyrazole-4-carboxamide;
[0084] 1-Ethyl-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-5-[3-fluoro-5-(propan-2-ylamino)pyridin-2-yl]pyrazole-4-carboxamide;
[0085] 5-[6-(Cyclopropylamino)-2-fluoropyridin-3-yl]-1-(oxetan-3-yl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide;
[0086] 5-[6-(Cyclopropylamino)-2-fluoropyridin-3-yl]-1-(oxetan-3-yl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide;
[0087] 5-[6-(Cyclopropylamino)-2-fluoropyridin-3-yl]-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-1-(oxacyclohexan-4-yl)pyrazole-4-carboxamide;
[0088] 5-[6-(Cyclopropylamino)-2-fluoropyridin-3-yl]-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-1-(oxacyclohexan-4-yl)pyrazole-4-carboxamide;
[0089] N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-5-[2-fluoro-6-(propan-2-ylamino)pyridin-3-yl]-1-(oxacyclohexan-4-yl)pyrazole-4-carboxamide;
[0090] 5-[2-Fluoro-6-(propan-2-ylamino)pyridin-3-yl]-1-(oxacyclohexan-4-yl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide;
[0091] 5-[6-(Ethylamino)-2-fluoropyridin-3-yl]-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-1-(oxacyclohexan-4-yl)pyrazole-4-carboxamide;
[0092] 3-[6-(Cyclopropylamino)-2-fluoropyridin-3-yl]-1-ethyl-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide;
[0093] 3-[6-(Cyclopropylamino)-2-fluoropyridin-3-yl]-1-ethyl-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide;
[0094] 1-Ethyl-3-[2-fluoro-6-(propylamino)pyridin-3-yl]-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide;
[0095] 1-Ethyl-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-3-[2-fluoro-6-(propylamino)pyridin-3-yl]pyrazole-4-carboxamide;
[0096] 1-tert-Butyl-3-[6-(cyclopropylamino)-2-fluoropyridin-3-yl]-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide;
[0097] 1-tert-Butyl-3-[6-(cyclopropylamino)-2-fluoropyridin-3-yl]-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide;
[0098] 3-[6-(Cyclopropylamino)-2-fluoropyridin-3-yl]-1-(oxacyclohexan-4-yl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide;
[0099] 3-[6-(Cyclopropylamino)-2-fluoropyridin-3-yl]-N-[(3S)-9-fluoro-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepine -3-yl]-1-(oxacyclohexan-4-yl)-1H-pyrazole-4-carboxamide;
[0100] 3-[6-(Cyclopropylamino)-2-fluoropyridin-3-yl]-N-[(3S)-9-fluoro-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepine -3-yl]-1-(2,2,2-trifluoroethyl)-1H-pyrazole-4-carboxamide;
[0101] (3-[6-(Cyclopropylamino)-2-fluoropyridin-3-yl]-1-(4,4-difluorocyclohexyl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide;
[0102] 3-[6-(Cyclopropylamino)-2-fluoropyridin-3-yl]-1-(4,4-difluorocyclohexyl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide;
[0103] 3-[6-(Cyclopropylamino)-2-fluoropyridin-3-yl]-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-1-(oxetan-3-yl)pyrazole-4-carboxamide;
[0104] 3-[6-(Cyclopropylamino)-2-fluoropyridin-3-yl]-1-(oxetan-3-yl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide;
[0105] -ethyl-5-(3-fluoro-5-(methylamino)pyridin-2-yl)-N-((S)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepine -3-yl)-1H-pyrazole-4-carboxamide;
[0106] 1-Ethyl-5-(5-(ethylamino)-3-fluoropyridin-2-yl)-N-((S)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepine -3-yl)-1H-pyrazole-4-carboxamide;
[0107] 5-[6-(Ethylamino)-2-fluoropyridin-3-yl]-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-1-(oxetan-3-yl)pyrazole-4-carboxamide;
[0108] N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-5-[2-fluoro-6-(propan-2-ylamino)pyridin-3-yl]-1-(oxetan-3-yl)pyrazole-4-carboxamide;
[0109] 5-[6-(Ethylamino)-2-fluoropyridin-3-yl]-1-(oxacyclohexan-4-yl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide;
[0110] 5-(4-cyclopropyl-2-fluorophenyl)-1-(oxacyclohexan-4-yl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide;
[0111] 5-(4-cyclopropyl-2-fluorophenyl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-1-(oxacyclohexan-4-yl)pyrazole-4-carboxamide;
[0112] 5-(2-Fluoro-4-propan-2-ylphenyl)-1-(oxacyclohexan-4-yl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide;
[0113] 5-(4-ethyl-2-fluorophenyl)-1-(oxacyclohexan-4-yl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide;
[0114] 5-(4-ethyl-2-fluorophenyl)-1-(oxacyclohexan-4-yl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide;
[0115] 5-(5-cyclopropyl-2-fluoropyridin-3-yl)-1-ethyl-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide;
[0116] 5-(6-cyclopropyl-2-fluoropyridin-3-yl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-1-(oxacyclohexan-4-yl)pyrazole-4-carboxamide;
[0117] 5-(5-cyclopropyl-2-fluoropyridin-3-yl)-1-(oxacyclohexan-4-yl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide;
[0118] 5-(5-cyclopropyl-2-fluoropyridin-3-yl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-1-(oxacyclohexan-4-yl)pyrazole-4-carboxamide;
[0119] 5-(6-ethyl-2-fluoropyridin-3-yl)-1-(oxacyclohexan-4-yl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide;
[0120] 5-(6-ethyl-2-fluoropyridin-3-yl)-1-(oxacyclohexan-4-yl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide;
[0121] 3-Ethoxy-1-ethyl-5-(2-fluorophenyl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide;
[0122] 3-Ethoxy-1-ethyl-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-5-(2-fluorophenyl)pyrazole-4-carboxamide;
[0123] 5-[6-(Cyclopropylamino)pyridin-3-yl]-1-(oxacyclohexan-4-yl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide;
[0124] 5-[6-(Cyclopropylamino)-2-fluoropyridin-3-yl]-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-1-(1-methylpiperidin-4-yl)pyrazole-4-carboxamide;
[0125] 1-(Oxan-4-yl)-5-[6-(propan-2-ylamino)pyridin-3-yl]-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide;
[0126] 5-(4-ethyl-2-fluorophenyl)-1-(1-methylpiperidin-4-yl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide;
[0127] and pharmaceutically acceptable salts thereof.
[0128] The compounds of the present invention may contain asymmetric or chiral centers and therefore exist in different stereoisomeric forms. It is intended that all stereoisomeric forms of the compounds of the present invention, including but not limited to diastereomers, enantiomers and atropisomers, as well as mixtures thereof such as racemic mixtures, form part of the present invention. Compounds of formula (I) containing one or more chiral centers may be used in enantiomerically or diastereomerically pure form or in the form of isomeric mixtures.
[0129] The present invention includes all geometric and positional isomers of the compounds of the present invention as defined above. For example, if the compounds of the present invention contain double bonds or fused rings, cis- and trans-forms and mixtures thereof are all included within the scope of the present invention. Single positional isomers and positional isomer mixtures are also within the scope of the present invention.
[0130] The compounds of the present invention may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and it is intended that the present invention embrace both solvated and unsolvated forms.
[0131] The compounds of the present invention may exist in different tautomeric forms, and all of these forms are included within the scope of the present invention. The term "tautomer" or "tautomeric form" refers to structural isomers of different energies that can be interconverted through a low energy barrier. For example, proton tautomers (also referred to as prototropic tautomers) include interconversions through proton migration, such as keto-enol tautomerism. Valence tautomers include interconversions through the reorganization of some bonded electrons.
[0132] The compounds of the present invention can be prepared by the synthetic methods described in the examples below, or by analogy thereto using appropriate starting materials and methods well known to skilled chemists.
[0133] Benzodiazepines of formula (I) The derivatives can be converted into their pharmaceutically acceptable salts by conventional methods, and the salts can be converted into free compounds. The derivative can be contacted with a pharmaceutically acceptable acid to form a pharmaceutically acceptable salt. A pharmaceutically acceptable salt is a salt with a pharmaceutically acceptable acid or base.
[0134] Pharmaceutically acceptable acids include inorganic acids such as hydrochloric acid, sulfuric acid, phosphoric acid, pyrophosphoric acid, hydrobromic acid or nitric acid; and organic acids such as citric acid, fumaric acid, maleic acid, malic acid, ascorbic acid, succinic acid, tartaric acid, benzoic acid, acetic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid or p-toluenesulfonic acid. Pharmaceutically acceptable bases include alkali metal (e.g., sodium or potassium) and alkaline earth metal (e.g., calcium or magnesium) hydroxides; and organic bases such as alkylamines, arylalkylamines and heterocyclic amines.
[0135] The compounds of the present invention have been found to be inhibitors of respiratory syncytial virus (RSV) in biological tests. They have effective anti-RSV activity and a combination of good bioavailability and good solubility properties. This combination of properties makes the compound useful in treatment and superior to many compounds disclosed in the prior art references discussed above as candidate drugs.
[0136] Therefore, the present invention further provides a compound for use in a method of treatment of the human or animal body by therapy which is a benzodiazepine of formula (I) as defined above. derivatives or pharmaceutically acceptable salts thereof.
[0137] The present invention also provides the compounds of this invention as defined above, for the treatment or prevention of RSV infection method. Still further, the present invention provides the compounds of this invention as defined above in the preparation of medicines for the treatment or prevention of RSV infection purposes. Therefore, the object that suffers from or is susceptible to RSV infection can be treated by including giving the compounds of this invention as defined above to it. The condition of the object can be improved or alleviated therefrom.
[0138] RSV infection is generally a respiratory tract infection. RSV infection can be the infection of children (e.g., children under ten years old or infants under two years old). In one embodiment, the invention provides compounds as defined above, for the treatment or prevention of RSV infection in pediatric patients. Alternatively, infection can be the infection of mature or elderly adults (e.g., adults over 60 years old, adults over 70 years old or adults over 80 years old). The invention further provides compounds, for the treatment or prevention of RSV infection in elderly patients.
[0139] The RSV infection can be an infection in an immunocompromised individual or an individual suffering from COPD or CHF. In another embodiment, the RSV infection is an infection in an uncompromised individual (eg, an otherwise healthy individual).
[0140] The compounds of the present invention can be administered in various dosage forms, for example, orally, such as in the form of tablets, capsules, sugar-coated or film-coated tablets, liquid solutions or suspensions; or parenterally, such as intramuscularly, intravenously or subcutaneously. The compounds can therefore be administered by injection, infusion or by inhalation or atomization. The compounds are preferably administered by oral administration.
[0141] Dosage depends on various factors, including patient's age, body weight and condition and administration route. Daily dose can change within wide limits, and will be adjusted according to individual requirements in each specific case. However, generally, the dosage adopted by each administration route when compound is administered to adults alone is 0.0001 to 650mg / kg, most often in the range of 0.001 to 10mg / kg body weight, for example 0.01 to 1mg / kg. This dosage can be given, for example, 1 to 5 times a day. For intravenous injection, suitable daily dose is 0.0001 to 1mg / kg body weight, preferably 0.0001 to 0.1mg / kg body weight. Daily dose can be given as a single dose or according to a divided dose plan.
[0142] Unit dosage forms such as tablets or capsules will generally contain 1-250 mg of active ingredient. For example, a compound of formula (I) can be administered to a human patient once, twice or three times a day at a dosage of 100-250 mg. For example, a compound of formula (I) can be administered to a human patient once, twice or three times a day at a dosage of 100-250 mg.
[0143] The compound of formula (I) and its pharmaceutically acceptable salt can be used alone. Alternatively, it can be administered in the form of a pharmaceutical composition. Therefore, the present invention also provides a pharmaceutical composition, which includes a compound of formula (I) as defined above or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable adjuvant, diluent or carrier. The conventional procedure for selecting and preparing appropriate pharmaceutical preparations is described in, for example, "Pharmaceuticals-The Science of Dosage Form Designs", ME Aulton, Churchill Livingstone, 1988.
[0144] Depending on the mode of administration, the pharmaceutical composition will preferably comprise 0.05 to 99% w (weight percent), more preferably 0.05 to 80% w, still more preferably 0.10 to 70% w, even more preferably 0.10 to 50% w of active ingredient, all weight percentages being based on the total composition.
[0145] The present invention further provides a process for preparing a pharmaceutical composition of the present invention, which comprises mixing a compound of formula (I) as defined above or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable adjuvant, diluent or carrier.
[0146] The compounds of the present invention can be given in various dosage forms. Therefore, they can be administered orally, for example as tablets, lozenges, lozenges, aqueous or oily suspensions, solutions, dispersible powders or granules. The compounds of the present invention can also be administered parenterally, whether subcutaneously, intravenously, intramuscularly, intrasternal, transdermally, by infusion techniques or by inhalation or atomization. The compounds can also be administered as suppositories.
[0147] The solid oral form of the pharmaceutical composition of the present invention may contain (together with the active compound) a diluent such as lactose, dextrose, sucrose, cellulose, corn starch or potato starch; a lubricant such as silicon dioxide, talc, stearic acid, magnesium stearate or calcium stearate, and / or polyethylene glycol; a binder such as starch, gum arabic, gelatin, methylcellulose, carboxymethylcellulose or polyvinylpyrrolidone; a disaggregating agent such as starch, alginic acid, alginate or sodium starch glycolate; an effervescent mixture; a dye; a sweetener; a wetting agent such as lecithin, polysorbate, lauryl sulfate (ester); and, in general, non-toxic and pharmacologically inactive substances used in pharmaceutical preparations. Such pharmaceutical preparations can be prepared in a known manner, for example, by mixing, granulating, tabletting, sugar coating or film coating processes.
[0148] Liquid dispersions for oral administration may be syrups, emulsions and suspensions. Syrups may contain, for example, sucrose or sucrose and glycerol and / or mannitol and / or sorbitol as carriers.
[0149] Suspensions and emulsions can contain, for example, natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose or polyvinyl alcohol as carriers. Suspensions or solutions for intramuscular injection can (together with the active compound) contain a pharmaceutically acceptable carrier, such as sterile water, olive oil, ethyl oleate, glycols, such as propylene glycol, and, if desired, an appropriate amount of lidocaine hydrochloride. Further suitable carriers for suspensions include sterile water, hydroxypropyl methylcellulose (HPMC), polysorbate 80, polyvinyl pyrrolidone (PVP), aerosol AOT (i.e., 1,2-bis(2-ethylhexyloxycarbonyl) ethanesulfonic acid sodium), pluronic F127 and / or captisol (i.e., sulfobutyl ether-β-cyclodextrin).
[0150] The compounds of the invention may, for example, be formulated as an aqueous suspension in a carrier selected from:
[0151] (i) 0.5% w / v hydroxypropyl methylcellulose (HPMC) / 0.1% w / v polysorbate 80;
[0152] (ii) 0.67% w / v polyvinylpyrrolidone (PVP) / 0.33% w / v aerosol AOT (sodium 1,2-bis(2-ethylhexyloxycarbonyl)ethanesulfonate);
[0153] (iii) 1% w / v pluronic F 127; and
[0154] (iv) 0.5% w / v Polysorbate 80.
[0155] The carrier can be prepared by standard procedures known to those skilled in the art. For example, each of carriers (i) to (iv) can be prepared by weighing the desired amount of excipient into a suitable container, adding about 80% of the final volume of water, and magnetic stirring until a solution is formed. The carrier is then made up to volume with water. An aqueous suspension of the compound of formula I can be prepared by weighing the desired amount of the compound of formula I into a suitable container, adding 100% of the desired volume of the carrier, and magnetic stirring.
[0156] Solutions for injection or infusion may contain, for example, sterile water as a carrier, or preferably they may be in the form of sterile aqueous isotonic saline solutions.
[0157] The compounds of the present invention can also be administered in combination with other compounds for the treatment of viral infections. Therefore, the present invention further relates to combination therapy, wherein the compounds of the present invention or their pharmaceutically acceptable salts or pharmaceutical compositions or preparations comprising the compounds of the present invention are administered synchronously or sequentially or as a combined preparation with one or more other therapeutic agents for the treatment or prevention of viral infections, specifically RSV infections.
[0158] In this document, where the term "combination" is used, it is understood that this refers to simultaneous, separate or sequential administration. In one aspect of the invention, "combination" refers to simultaneous administration. In another aspect of the invention, "combination" refers to separate administration. In a further aspect of the invention, "combination" refers to sequential administration. In the case of sequential or separate administration, the delay in administering the second component should not cause a loss of the beneficial effects of the combination.
[0159] Suitable therapeutic agents for combination therapy include
[0160] (i) RSV nucleocapsid (N) protein inhibitors;
[0161] (ii) other RSV protein inhibitors, such as those that inhibit the phosphoprotein (P) protein and the large (L) protein;
[0162] (iii) anti-RSV monoclonal antibodies, such as F protein antibodies;
[0163] (iv) immunomodulatory toll-like receptor compounds;
[0164] (v) other respiratory virus antivirals, such as anti-influenza and anti-rhinovirus compounds; and / or
[0165] (vi) Anti-inflammatory compounds.
[0166] The RSV nucleocapsid (N) protein plays a key role in viral transcription and replication, mediating the interaction between genomic RNA and the RNA-dependent RNA polymerase encoded by the virus. The RSV P protein and L protein are components of the RNA-dependent RNA polymerase encoded by the RSV virus.
[0167] According to a further aspect of the present invention, there is provided a compound of formula (I) as defined above, or a pharmaceutically acceptable salt thereof, in combination with one or more of the therapeutic agents listed as (i) to (vi) above for use in treating RSV.
[0168] The following examples are used to further illustrate the present invention. The preparation examples relate to the preparation of starting materials and intermediates used to prepare the compounds of the examples. Neither the examples nor the preparation examples limit the present invention in any way.
[0169] Example
[0170] Reagents were obtained from commercial sources and used without further purification. Reactions were performed under anhydrous conditions using anhydrous solvents obtained from commercial sources. All temperatures are in °C. TLC was performed on aluminum backed silica gel plates with a 254 nM fluorescent indicator (median pore size ). Microwave reactions were performed using a Biotage Initiator. Flash column chromatography was performed using a Biotage Isolera One system using KP-Sil or Ultra silica columns or using an Isco CombiFlash Rf using FlashPure, RediSep Rf or RediSep Rf Gold silica columns. Reverse phase flash chromatography was performed using an Isco CombiFlash Rf and RP Flash C18 columns. NMR spectra were recorded at ambient probe temperature (nominal 298K) on a 400, 500, 600 or 700 MHz spectrometer. Chemical shifts (δ) are given in ppm and are calibrated by using the residual peak of the solvent as an internal standard (CDCl3, δ = 7.26 ppm; DMSO-d6, δ = 2.50 ppm). Coupling constants are given in Hertz (Hz). LRMS was performed using an Advion Plate Express expression ion source equipped with an APCI ion source. L Compact mass spectrometer to record.
[0171] LCMS analysis was performed using a Waters Acquity UPLC with a Waters X-Select UPLC C18 column (1.7 μm; 2.1×30 mm) and a 3 min (method A) or 10 min method (method B), or using an Agilent UPLC with a Waters X-Select C18 (2.5 μm; 4.6×30 mm) and a 3 min (method C) or 10 min method (method D). It was performed at 40° C. and 0.77 mL / min and a linear 5-95% acetonitrile gradient appropriate to the lipophilicity of the compound. The aqueous portion of the mobile phase was 0.1% formic acid. LC-UV chromatograms were recorded between 210 and 400 nm using a Waters Acquity photodiode array detector. Mass spectra were recorded using a Waters Acquity QDa detector with ESI switched between positive and negative ion modes.
[0172] Preparation Example (3S)-3-amino-5-phenyl-1,3-dihydro-1,4-benzodiazepine -2-one and (3S)-3-amino-9-fluoro-5-phenyl-1,3-dihydro-1,4-benzodiazepine -2-ketone was prepared using the methods described in WO / 2004 / 026843, WO / 2005 / 090319 and WO / 2017 / 015449.
[0173] Abbreviations
[0174]
[0175] Preparation Example
[0176] 1A 1-Ethylpyrazole-4-carboxylic acid ethyl ester
[0177]
[0178] Iodoethane (1.89mL, 23.56mmol) is added to a solution of 1H-pyrazole-4-carboxylic acid ethyl ester (3.00g, 21.4mmol) and KCO (3.25g, 23.6mmol) in DMF (20mL), and the reaction mixture is stirred at rt for 23h. The reaction mixture is diluted with water (50mL), extracted with EtOAc (3×30mL), the combined organic phases are washed with water and brine (each 30mL), dried (NaSO), and concentrated under reduced pressure. Purification by flash chromatography (10-50% EtOAc / heptane) gives a white solid (3.10g, 86%). 1H NMR (400MHz, DMSO-d6) δ8.33 (d, J = 0.7Hz, 1H), 7.83 (d, J = 0.8Hz, 1H), 4.25–4.12 (m, 4H), 1.37 (t, J = 7.3Hz, 3H), 1.25 (t, J = 7.1Hz, 3H). LRMS m / z 169.0[M+H] +
[0179] 2A 1-ethyl-3-methyl-1H-pyrazole-4-carboxylic acid ethyl ester
[0180]
[0181] At 0 ° C, NaH (60% in mineral oil; 0.300g, 7.50mmol) was added to a solution of 3-methyl-1H-pyrazole-4-carboxylic acid ethyl ester (1.00g, 6.49mmol) in DMF (10mL) in portions. The reaction mixture was stirred for 5min, iodoethane (0.60mL, 7.42mmol) was added, and the reaction mixture was stirred overnight at rt. The reaction mixture was quenched with water (50mL), diluted with MTBE (50mL), separated and the aqueous phase was extracted with MTBE (2×20mL). The combined organic phase was washed with 1:1 water / brine (2×50mL), dried (MgSO4), and the solvent was removed under reduced pressure. A light yellow oil (840mg, 47%) was obtained by flash chromatography (0-30% EtOAc / isohexane). The material was a ~1:0.8 mixture of the desired regioisomer with ethyl 1-ethyl-5-methyl-1H-pyrazole-4-carboxylate as a minor product. It was used without further purification. 1 H NMR determines the ratio based on the delta pyrazole CH signal: 1 H NMR (500MHz, CDCl3) δ7.83 (s, 1H), 4.27 (q, J = 7.1Hz, 2H), 4.11 (q, J = 7.3Hz, 2H), 2.46 (s, 3H), 1.48 (t, J = 7.3Hz, 3H), 1.34 (t, J = 7.1Hz, 3H). LCMS (Method A)m / z 183.1[M+H] + , at 1.00 min. Minor product: ethyl 1-ethyl-5-methyl-1H-pyrazole-4-carboxylate. 1H NMR (500MHz, CDCl3) δ7.84 (s, 1H), 4.28 (q, J = 7.1Hz, 2H), 4.11 (q, J = 7.3Hz, 2H), 2.54 (s, 3H), 1.41 (t, J = 7.3Hz, 3H), 1.34 (t, J = 7.1Hz, 3H). LCMS(Method A)m / z183.1[M+H] + , at 1.00min.
[0182] 3A 1-Propan-2-ylpyrazole-4-carboxylic acid ethyl ester
[0183]
[0184] Cs2CO3 (3.7 g, 10.7 mmol) and 2-bromopropane (1.62 g, 13.2 mmol) were added to a solution of 1H-pyrazole-4-carboxylic acid ethyl ester (1.5 g, 10.7 mmol) in DMF (15 mL) and heated at 60 ° C for 2 h. The reaction mixture was diluted with water (150 mL) and extracted with MTBE (2×100 mL). The combined organic phases were washed with brine (50 mL), dried (Na2SO4) and the solvent was removed under reduced pressure. The residue was purified by flash chromatography (5-60% EtOAc / isohexane). Colorless oil (1.65 g, 81%). 1 H NMR (500 MHz, CDCl3) δ 7.92 (s, 1H), 7.91 (s, 1H), 4.59-4.49 (m, 1H), 4.28 (q, J = 7.1 Hz, 2H), 1.52 (d, J = 6.7 Hz, 6H), 1.33 (t, J = 7.1 Hz, 3H). LCMS (Method C): m / z 183.2 [M+H] + , at 1.03min.
[0185] 4A 5-amino-1-cyclopropylpyrazole-4-carboxylic acid ethyl ester
[0186]
[0187] At rt, NEt3 (2.57 mL, 18.42 mmol) was added dropwise over 45 min to a stirred solution of cyclopropylhydrazine hydrochloride (1.00 g, 9.21 mmol) and ethyl (ethoxymethylene)cyanoacetate (1.56 g, 9.21 mmol) in EtOH (10 mL), then heated at 40° C. for 16 h. The volatiles were removed under reduced pressure, and the residue was dissolved in CH2Cl2 (30 mL), washed with water (2×20 mL) and brine (20 mL), dried (Na2SO4) and the solvent removed under reduced pressure. Purification by flash chromatography (30% EtOAc: heptane) gave a yellow oil (725 mg, 40%). 1 H NMR (400MHz, DMSO-d6) δ7.37 (s, 1H), 6.23 (s, 2H), 4.15 (q, J = 7.1Hz, 2H), 3.26 (tt, J = 6.8, 4.1Hz, 1H), 1.23 (t, J = 7.1Hz, 3H), 1.02–0.86 (m, 4H). LRMS:196.2[M+H] +
[0188] 5A 5-Bromo-1-cyclopropylpyrazole-4-carboxylic acid ethyl ester
[0189]
[0190] A solution of copper (II) bromide (1001 mg, 4.48 mmol) in MeCN (7.7 mL) was cooled to 0 ° C. Tert-butyl nitrite (0.64 mL, 5.38 mmol) was added, and then intermediate 4A (700 mg, 3.59 mmol) in MeCN (7.7 mL) was added dropwise over 30 min. The reaction was stirred at 0 ° C for 30 min, the ice bath was removed, and then stirred at rt for 16 h. The mixture was poured into a solution of 6 Maq.HCl (20 mL) and extracted with CH2Cl2 (3×20 mL). The organic phase was washed with brine, dried (Na2SO4) and the solvent was removed under reduced pressure. Purification by flash chromatography (0-10% EtOAc: heptane) gave a colorless oil (694 mg, 75%). 1 H NMR (400MHz, DMSO-d6) δ7.92(s,1H),4.23(q,J=7.1Hz,2H),3.75–3.65(m,1H),1.27(t,J=7.1Hz,3H),1.12–1.03(m,4H). LRMS:259.1 / 261.1[M+H] +
[0191] 6A 5-bromo-1-(oxacyclohexane-4-yl)pyrazole-4-carboxylic acid ethyl ester
[0192] 7A 3-Bromo-1-(oxacyclohexan-4-yl)pyrazole-4-carboxylic acid ethyl ester
[0193]
[0194] 4-Methylbenzenesulfonic acid oxacyclohexane-4-ester (1.67 g, 6.53 mmol) was added to a solution of 3-bromo-1H-pyrazole-4-carboxylic acid ethyl ester (1.30 g, 5.93 mmol) and CsCO (2.63 g, 8.01 mmol) in DMF (10 mL) and heated at 80 ° C for 16 h. After cooling to rt, water (40 mL) was added and the mixture was extracted with EtOAc (3×20 mL). The organic phase was washed with water and brine (20 mL each), dried (NaSO) and the solvent was removed under reduced pressure. Intermediate 6A was purified by flash chromatography (10-80% EtOAc: heptane) as a white solid (445 mg, 25%). 1 H NMR(400MHz, DMSO-d6)δ8.05(s,1H),4.66(tt,J=11.3,4.3Hz,1H),4.24(q,J=7.1Hz,2H),4.01–3.91(m,2H) ,3.50(td,J=12.0,2.1Hz,2H),2.08–1.94(m,2H),1.83(ddd,J=12.6,4.4,2.0Hz,2H),1.27(t,J=7.1Hz,3H). LRMS:303.0 / 305.0[M+H] + .
[0195] Intermediate 7A (second eluting regioisomer) was obtained as a white solid (1018 mg, 57%). 1 H NMR(400MHz, DMSO-d6)δ8.43(s,1H),4.45(dd,J=10.5,5.0Hz,1H),4.22(q,J=7.1Hz, 2H), 4.00–3.88 (m, 2H), 3.48–3.36 (m, 2H), 2.04–1.83 (m, 4H), 1.27 (t, J = 7.1Hz, 3H). LRMS:303.4 / 305.4[M+H] + .
[0196] 8A 3-Bromo-1-(4,4-difluorocyclohexyl)pyrazole-4-carboxylic acid ethyl ester
[0197]
[0198] Prepared by a procedure analogous to that described for Intermediate 6A. 1H NMR (400MHz, CDCl3) δ7.86 (s, 1H), 4.28 (q, J = 7.1Hz, 2H), 4.25–4.12 (m, 1H), 2.36–2.04 (m, 6H), 2.04–1.73 (m, 2H), 1.32 (t, J = 7.1Hz, 3H). LRMS:317.3 / 319.3[M+H] + .
[0199] 9A 5-bromo-1-(oxetan-3-yl)pyrazole-4-carboxylic acid ethyl ester
[0200] 10A Ethyl 3-bromo-1-(oxetan-3-yl)pyrazole-4-carboxylate
[0201]
[0202] Prepared by a procedure similar to that described for Intermediate 6A using ethyl 3-bromo-1H-pyrazole-4-carboxylate (1.70 g, 7.76 mmol), 3-oxetanes-4-methylbenzenesulfonate (1.95 g, 8.50 mmol) and CsCO (3.43 g, 10.48 mmol) and heating at 90° C. for 22 h. Purification by flash chromatography (10-100% EtOAc:heptane) gave Intermediate 9A (first eluting regioisomer) as a white solid (640 mg, 30%). 1 H NMR (400MHz, DMSO-d6) δ8.15(s,1H),5.75(tt,J=7.4,6.2Hz,1H),4.98–4.85(m,4H),4.24(q,J=7.1Hz,2H),1.28(t,J=7.1Hz,3H). LRMS:275.5 / 277.5[M+H] + Intermediate 10A: (second eluting regioisomer), white solid (1.06 g, 50%). 1 HNMR (400MHz, DMSO-d6) δ8.50(s,1H),5.60(tt,J=7.5,6.1Hz,1H),4.94–4.77(m,4H),4.23(q,J=7.1Hz,2H),1.27(t,J=7.1Hz,3H). LRMS:275.5 / 277.5[M+H] + .
[0203] 11A Ethyl 3-bromo-1-ethylpyrazole-4-carboxylate
[0204]
[0205] Ethyl iodide (2.02 mL, 25.11 mmol) was added to a solution of ethyl 3-bromo-1H-pyrazole-4-carboxylate (5.00 g, 22.83 mmol) and K2CO3 (4.10 g, 29.67 mmol) in DMF (35 mL) and the reaction was stirred at rt for 16 h. Water (100 mL) was added and the mixture was extracted with EtOAc (3×50 mL). The organic phase was washed with water (2×50 mL) and brine (50 mL), dried (Na2SO4) and the solvent removed under reduced pressure. Purification by flash chromatography (10-25% EtOAc:heptane) gave a white solid (3.70 g, 66%). 1 H NMR (400MHz, DMSO-d6) δ8.39(s,1H),4.21(q,J=7.1Hz,2H),4.15(q,J=7.3Hz,2H),1.36(t, J =7.3Hz, 3H), 1.26 (t, J = 7.1Hz, 3H). LRMS:247.0 / 249.0[M+H] + .
[0206] 12A 3-Bromo-1-(2,2,2-trifluoroethyl)pyrazole-4-carboxylic acid ethyl ester
[0207]
[0208] Prepared by a procedure analogous to that described for Intermediate 11A using ethyl 3-bromo-1H-pyrazole-4-carboxylate (1.50 g, 6.85 mmol), 1,1,1-trifluoro-2-iodoethane (1.35 mL, 13.7 mmol) and Cs2CO3 (4.46 g, 13.7 mmol) in DMF (7 mL) and heating at 70°C for 3 h then at 40°C for 16 h. 1 H NMR (400MHz, CDCl3) δ8.01 (s, 1H), 4.71 (q, J = 8.1Hz, 2H), 4.35 (q, J = 7.1Hz, 2H), 1.39 (t, J = 7.1Hz, 3H). LRMS:301.2 / 303.2[M+H] + .
[0209] 13A 3-Bromo-1-(4,4-difluorocyclohexyl)pyrazole-4-carboxylic acid
[0210]
[0211] A solution of intermediate 8A (580 mg, 1.72 mmol) and LiOH (1M aq., 6.88 mL, 6.88 mmol) in THF:MeOH (1:1; 14 mL) was heated at 55°C for 1 h. The volatiles were removed under reduced pressure, and the residue was acidified to pH≈2 with HCl (1M aq.) and then extracted with EtOAc (3×15 mL). The combined organic extracts were washed with water and brine (15 mL each), dried (MgSO4), and the solvent was removed under reduced pressure to give a white solid (464 mg, 87%). 1 H NMR (400MHz, DMSO-d6) δ12.57(s,1H),8.36(s,1H),4.47–4.38(m,1H),2.23–1.78(m,8H). LRMS:289.1 / 291.1[M+H] + .
[0212] The following intermediate compounds were prepared by the same general procedures as described for Intermediate 13A.
[0213]
[0214]
[0215] 14A 3-Bromo-1-tert-butylpyrazole-4-carboxylic acid
[0216]
[0217] A solution of ethyl 3-bromo-1H-pyrazole-4-carboxylate (1.00 g, 4.57 mmol) in 3-methyl-1-butanol (4 mL) was warmed to 30 ° C, then sulfuric acid (0.97 mL, 18.26 mmol) was slowly added. The reaction was stirred at 30 ° C for 30 min, then heated to 80 ° C for 1.5 h. The reaction was cooled to rt, diluted with EtOAc (15 mL), and the organic layer was separated, washed with water (10 mL), dried (MgSO4), and the solvent was removed under reduced pressure to obtain crude ethyl 3-bromo-1-tert-butylpyrazole-4-carboxylate as a colorless oil (1.40 g), which was used without further purification. A solution of crude 3-bromo-1-tert-butylpyrazole-4-carboxylic acid ethyl ester (1.40 g, 5.09 mmol) and LiOH (1M aq, 10.18 mL, 10.18 mmol) in THF:MeOH (1:1, 20 mL) was heated at 55 ° C for 1 h. Volatiles were removed under reduced pressure, and the residue was acidified to pH ≈ 2 with 1M HCl (aq.), then extracted with EtOAc (3×15 mL). The combined organic extracts were washed with water and brine (each 15 mL), dried (MgSO ) and concentrated under reduced pressure to give a white solid (815 mg, 72%). 1 HNMR (400MHz, DMSO-d6) δ12.59(s,1H),8.31(s,1H),1.51(s,9H). LRMS:247.3 / 249.3[M+H] + .
[0218] 15A Benzyl 3-bromo-1-(2,2,2-trifluoroethyl)pyrazole-4-carboxylate
[0219]
[0220] Diazabicyclo [5.4.0] undec-7-ene (0.15 mL, 0.97 mmol) was added to a solution of intermediate 13D (204 mg, 0.75 mmol) in DMSO (3 mL) under a nitrogen atmosphere and stirred for 5 min at rt. Benzyl bromide (0.09 mL, 0.75 mmol) in DMSO (3 mL) was added and the reaction was stirred for 2 h at rt. The reaction was quenched with water and brine (20 mL each) and extracted with EtOAc (3×20 mL). The organic phase was washed with brine (2×20 mL), dried (Na2SO4), and the solvent was removed under reduced pressure. Purification by flash chromatography (60-100% EtOAc: heptane) gave a white solid (218 mg, 80%). 1H NMR (400MHz, DMSO-d6) δ8.59 (s, 1H), 7.48–7.32 (m, 5H), 5.28 (s, 2H), 5.21 (q, J = 8.9Hz, 2H). LRMS:363.3 / 365.3[M+H] + .
[0221] The following intermediate compounds were prepared by the same general procedures as described for Intermediate 15A.
[0222]
[0223]
[0224] 16A (6-chloro-5-fluoropyridin-3-yl)(methyl)carbamic acid tert-butyl ester
[0225]
[0226] A vial was charged with added 5-bromo-2-chloro-3-fluoropyridine (100 mg, 0.475 mmol), tert-butyl methylcarbamate (75 mg, 0.572 mmol) and Cs2CO3 (217 mg, 0.665 mmol), 1,4-dihydropyridine (100 mg, 0.475 mmol), and 1,4-dihydropyridine (75 mg, 0.572 mmol). alkane (2mL), and the reaction mixture is degassed with nitrogen. Pd2(dba)3(9mg, 9.83μmol) and Xantphos (22mg, 0.038mmol) are added, the reaction mixture is evacuated and purged with nitrogen (×3), and heated at 110°C overnight. Water (10mL) and EtOAc (10mL) are added and the phases are separated. The aqueous phase is extracted with EtOAc (2×10mL), and the combined organic extracts are washed with brine (20mL), dried (MgSO4), and the solvent is removed under reduced pressure. The residue is purified by flash chromatography (0-20% EtOAc / isohexane) to obtain a light yellow gum (52mg, 41%). 1 H NMR (500MHz, CDCl3) δ8.17 (d, J = 2.4 Hz, 1H), 7.57 (d, J = 9.6 Hz, 1H), 3.31 (s, 3H), 1.50 (s, 9H). LCMS (Method A): m / z261.1[M+H] + , at 1.54min.
[0227] 17A 5-(3,5-difluoropyridin-2-yl)-1-ethylpyrazole-4-carboxylic acid ethyl ester
[0228]
[0229] A solution of intermediate 1A (500 mg, 2.97 mmol) in anhydrous THF (5 mL) was degassed with nitrogen. The solution was cooled to -78 ° C and LDA (2.0 M in THF; 1.8 mL, 3.60 mmol) was added, stirred at -78 ° C for 1 min, and then zinc (II) chloride (2.0 M in 2-Me THF; 1.8 mL, 3.60 mmol) was added. The reaction was warmed to rt and degassed with nitrogen. 2-Bromo-3,5-difluoropyridine (690 mg, 3.56 mmol) and Pd(PPh3)4 (172 mg, 0.15 mmol) were added, the reaction mixture was evacuated and purged with nitrogen, and then heated at 70 ° C under nitrogen overnight. 1M aq.HCl (50 mL) and EtOAc (50 mL) were added and the phases were separated. The aqueous phase was extracted with EtOAc (2 x 20 mL), the combined organic phases were washed with brine (100 mL), dried (MgSO4) and the solvent removed under reduced pressure. The residue was purified by flash chromatography (0-40% MTBE / isohexane) to give a pale yellow oil (523 mg, 62%). 1 H NMR (500MHz, CDCl3) δ8.49 (d, J=2.4Hz, 1H), 8.02 (s, 1H), 7.36 (td, J=8.3, 2.4Hz, 1H), 4. 18(q,J=7.1Hz,2H), 4.10(q,J=7.3Hz,2H), 1.39(t,J=7.2Hz,3H), 1.20(t,J=7.1Hz,3H). LCMS (Method A): m / z 282.1[M+H] + , at 1.23min.
[0230] The following intermediate compounds were prepared by the same general procedures as described for Intermediate 17A.
[0231]
[0232] 18A 1-cyclopropyl-5-(2,6-difluoropyridin-3-yl)pyrazole-4-carboxylic acid ethyl ester
[0233]
[0234] In a microwave vial, intermediate 5A (500 mg, 1.93 mmol), 2,6-difluoropyridine-3-boronic acid (337 mg, 2.12 mmol), K2CO3 (2M aqueous solution; 4.82 mL, 9.65 mmol) were added to 1,4-difluoropyridine-3-boronic acid. The solution in 2-nitropropane (7 mL) was purged with nitrogen for 15 min. Pd(PPh3)4 (223 mg, 0.19 mmol) was added and the sealed vial was heated at 110 °C for 17 h. The reaction was cooled to rt, purged with nitrogen for 15 min, additional 2,6-difluoropyridine-3-boronic acid (61.3 mg, 0.39 mmol) and Pd(PPh3)4 (55.8 mg, 0.05 mmol) were added and heated at 110 °C for another 4 h. The reaction was cooled to rt, water (20 mL) was added and extracted with EtOAc (3×20 mL). The combined organic phases were washed with brine (20 mL), dried (Na2SO4) and the solvent removed under reduced pressure. Purification by flash chromatography (10-35% EtOAc:heptane) gave a yellow oil (206 mg, 18%) which was purified by 1 H NMR, product to dehalogenated starting material ratio ~1:1. Used without further purification. Intermediate 18A: 1 H NMR (400MHz, DMSO-d6) δ8.51–8.42(m,1H),7.97(s,1H),7.42(ddd,J=8.2,2.5,0.7Hz,1H),4.08(q, J=7.1Hz,2H),3.58(tt,J=7.4,3.8Hz,1H),1.13–1.04(m,5H),1.04–0.92(m,4H),0.92–0.83(m,2H). LRMS m / z:294.1[M+H] + . By-product: 1-cyclopropyl-1H-pyrazole-4-carboxylic acid ethyl ester: 1 H NMR (400 MHz, DMSO-d6) 1 HNMR(400MHz,DMSO-d6)δ8.37(s,1H),7.81(d,J=0.7Hz,1H),4.20(q,J=7.1H z,2H),3.80(tt,J=7.5,3.9Hz,1H),1.25(t,J=7.1Hz,3H),1.13–0.82(m,4H). LRMS m / z:181.1[M+H] + .
[0235] 19A Benzyl 3-(2,6-difluoropyridin-3-yl)-1-(oxetan-3-yl)pyrazole-4-carboxylate
[0236]
[0237] A microwave vial containing 2,6-difluoropyridine-3-boronic acid (413 mg, 2.60 mmol), intermediate 15F (585 mg, 1.74 mmol) and XPhos Pd G2 (7.5 mol%; 102 mg, 0.130 mmol) was evacuated and filled with N2 (3×). THF (10 mL) and K3PO4 (2M aq; 1.74 mL, 3.47 mmol) were added, both degassed with N2 for ~15 min, and the vial was heated at 80°C for 30 min by MWI. The volatiles were removed under reduced pressure and the residue was purified by flash chromatography (20 to 45% EtOAc:heptane) to give a yellow oil (520 mg, 81%). 1 H NMR (400MHz, DMSO-d6) δ8.68(s,1H),8.28(q,J=8.5Hz,1H),7.39–7.21(m,6H),5.73–5.61(m,1H),5.18(s,2H),4.96–4.90(m,4H). LRMS m / z:[M+H] + 372.5.
[0238] The following intermediate compounds were prepared using similar procedures.
[0239]
[0240]
[0241] 20A 1-ethyl-5-(2-fluoro-6-(methylamino)pyridin-3-yl)-1H-pyrazole-4-carboxylic acid ethyl ester
[0242]
[0243] NEt3 (40 μL, 0.287 mmol) and methylamine (2.0 M in THF; 72 μL, 0.144 mmol) were added to a solution of intermediate 17B (40.5 mg, 0.144 mmol) in THF (1 mL) and stirred overnight at rt. Further methylamine (2.0 M in THF; 72 μL, 0.144 mmol) was added and the reaction was stirred overnight at rt. Water (10 mL) and EtOAc (10 mL) were added, the phases were separated, and the aqueous phase was extracted with EtOAc (2×5 mL). The combined organic phases were washed with brine (10 mL), dried (MgSO4), and the solvent was removed under reduced pressure. Purification by flash chromatography (0-50% EtOAc / isohexane) gave a colorless gum (18 mg, 42%). 1H NMR(500MHz, CDCl3)δ8.01(s,1H),7.50(dd,J=9.5,8.3Hz,1H),6.34(dd,J=8.3,1.9Hz,1H),4.85-4.81(m,1H) ,4.19(q,J=7.1Hz,2H),4.04-4.00(m,2H),2.99(d,J=5.1Hz,3H),1.40(t,J=7.2Hz,3H),1.23(t,J=7.1Hz,3H). LCMS (Method A): m / z 293.2[M+H] + , at 1.19min.
[0244] 21A 1-ethyl-5-(6-(ethylamino)-2-fluoropyridin-3-yl)-1H-pyrazole-4-carboxylic acid ethyl ester
[0245]
[0246] DIPEA (130 μl, 0.744 mmol) and ethylamine (68% in water, 38 μL, 0.466 mmol) were added to a solution of intermediate 17B (100 mg, 0.356 mmol) in THF (1 mL) and the reaction was heated at 60° C. overnight. The reaction mixture was diluted with CH2Cl2 (10 mL) and water (10 mL), passed through a phase separator and dried under reduced pressure. The crude product was purified by flash chromatography (0-50% EtOAc / isohexane) to give a colorless gum (57 mg, 48%). 1 H NMR (500MHz, CDCl3) δ8.03(s,1H),7.52(dd,J=9.3,8.3Hz,1H),6.36(dd,J=8.4,1.7Hz,1H),5.31(s,1H),4.20(q,J=7 .1Hz,2H),4.11-3.98(m,2H),3.38(q,J=7.2Hz,2H),1.46-1.37(m,3H),1.31(t,J=7.2Hz,3H),1.24(t,J=7.1Hz,3H). LCMS (Method A): m / z 307.1[M+H] + , at 1.31min.
[0247] The following intermediate compounds were prepared using similar procedures as used for Intermediate 21A.
[0248]
[0249]
[0250] 22A 1-cyclopropyl-5-[6-(ethylamino)-2-fluoropyridin-3-yl]pyrazole-4-carboxylic acid ethyl ester
[0251]
[0252] A solution of crude intermediate 18A (50 mg, 0.170 mmol), ethylamine (2 M in MeOH; 34 μL, 0.511 mmol) and NEt3 (95 μL, 0.682 mmol) in THF (0.49 mL) was heated at 50 °C for 18.5 h in a sealed vial under nitrogen. Additional ethylamine (2 M in MeOH; 34 μL, 0.511 mmol) was added and the reaction was heated at 50 °C for 4 h. The volatiles were removed under reduced pressure and the residue was purified by flash chromatography (10-30% EtOAc / heptane) to give a colorless oil (32.0 mg, 59%). TLC R f 0.56 (heptane / EtOAc 1:1). LRMS m / z: 294.1 [M+H] + .
[0253] 23A 1-Cyclopropyl-5-[6-(cyclopropylamino)-2-fluoropyridin-3-yl]pyrazole-4-carboxylic acid ethyl ester
[0254]
[0255] Prepared by a procedure analogous to that described for Intermediate 22A using cyclopropylamine (71 μL, 1.02 mmol) and heating at 60° C. for 19 h. TLC R f 0.45 (heptane / EtOAc 1:1). LRMS m / z: 331.3 [M+H] + .
[0256] 24A 5-[5-(Cyclopropylamino)-3-fluoropyridin-2-yl]-1-ethylpyrazole-4-carboxylic acid ethyl ester
[0257]
[0258] Cyclopropylamine (500 μL, 7.21 mmol) was added to a solution of intermediate 17A (200 mg, 0.711 mmol) and DIPEA (150 μL, 0.861 mmol) in DMSO (1 mL) and heated at 140 °C for 3 h by MWI. Water (20 mL) and EtOAc (20 mL) were added, the phases were separated and the aqueous phase was extracted with EtOAc (2×10 mL). The combined organic phases were washed with water and brine (20 mL each), dried (MgSO4), and the solvent was evaporated under reduced pressure. Purification by flash chromatography (10-60% EtOAc / isohexane) gave a colorless oil (215 mg, 94%). 1 H NMR (500MHz, DMSO-d6) δ8.04(s,1H),8.00(s,1H),6.99–6.92(m,1H),4.62(s,1H),4.19(q,J=7.1Hz,2H),4.13(q,J=7. 2Hz,2H),2.51(s,1H),1.64(s,1H),1.39(t,J=7.1Hz,3H),1.22(t,J=7.2Hz,3H),0.90–0.82(m,2H),0.65–0.59(m,2H). LCMS (Method A)m / z 319.2[M+H] + , at 1.30min.
[0259] The following intermediate compounds were prepared by similar procedures to those used for Intermediate 24A.
[0260]
[0261] 25A 1-ethyl-5-[2-fluoro-6-[(1-methylcyclopropyl)amino]pyridin-3-yl]pyrazole-4-carboxylic acid ethyl ester
[0262]
[0263] Prepared by an analogous procedure to that described for Intermediate 24A using Intermediate 17B (100 mg, 0.338 mmol), 1-methylcyclopropyl-1-amine hydrochloride (182 mg, 1.69 mmol) and DIPEA (350 μL, 2.01 mmol) and heating at 120° C. for 1 h by MWI. After similar work-up, purification by flash chromatography on RP Flash C18 (25-75% MeCN / water 0.1% formic acid) gave a light yellow gum (70 mg, 62%). 1H NMR (500MHz, DMSO-d6) δ8.02(s,1H),7.55(dd,J=9.5,8.2Hz,1H),6.65(dd,J=8.2,1.9Hz,1H),4.19(q,J=7.1Hz,2H) ,4.08–3.96(m,2H),1.44(s,3H),1.41(t,J=7.2Hz,3H),1.23(t,J=7.1Hz,3H),0.88–0.85(m,2H),0.78–0.75(m,2H). LCMS (Method A): m / z 333.2[M+H] + , at 1.44min.
[0264] 26A 5-[6-(Cyclopropylamino)-2-fluoropyridin-3-yl]-1-propan-2-ylpyrazole-4-carboxylic acid ethyl ester
[0265]
[0266] A solution of Intermediate 17F (100 mg, 0.339 mmol) and cyclopropylamine (117 μL, 1.693 mmol) in DMSO (1 mL) was heated at 50° C. for 16 h. Workup and purification similar to that described for Intermediate 24A gave a colorless oil (100 mg, 82%). 1 H NMR(500MHz, CDCl3)δ8.02(s,1H),7.57–7.50(m,1H),6.68(dd,J=8.2,1.8Hz,1H),5.33(s,1H),4.33–4.24(m,1H),,4.17(q,J=7.1H z,2H),2.61–2.53(m,1H),1.49(d,J=6.6Hz,3H),1.39(d,J=6.6Hz,3H),1.21(t,J=7.1Hz,3H),0.87–0.80(m,2H),0.64–0.59(m,2H). LCMS (Method A)m / z 333[M+H] + , at 1.35min.
[0267] 27A 1-ethyl-5-[2-fluoro-4-(propan-2-ylamino)phenyl]pyrazole-4-carboxylic acid ethyl ester
[0268]
[0269] A microwave vial containing Intermediate 17D (100 mg, 0.29 mmol), Pd2(dba)3 (13 mg, 0.010 mmol), BINAP (18 mg, 0.030 mmol), potassium tert-butoxide (43 mg, 0.38 mmol) and isopropylamine (29 μL, 0.35 mmol) was evacuated and purged with N2, then DMSO (1 mL) was added. The reaction mixture was degassed with nitrogen and then heated at 110°C for 1 h. Water (20 mL) and EtOAc (10 mL) were added, the phases separated, and the aqueous phase extracted with EtOAc (2×10 mL). The combined organic extracts were washed with water, brine (20 mL each), dried (MgSO4), and the solvent removed under reduced pressure. The residue was purified by flash chromatography (0-50% EtOAc / isohexane) to give a colorless gum (22.0 mg, 23%). LCMS (Method A) m / z 320.2 [M+H] + , at 1.52min.
[0270] 28A 1-ethyl-5-(6-(ethylamino)-2-fluoropyridin-3-yl)-3-methyl-1H-pyrazole-4-carboxylic acid ethyl ester
[0271]
[0272] Prepared by an analogous procedure to Intermediate 21A using Intermediate 17E (100 mg, 0.254 mmol), DIPEA (0.1 mL, 0.573 mmol) and ethylamine - 68% in water (0.4 mL, 4.9 mmol) in THF (1 mL). The reaction was carried out at 50°C for 2 h. 1 H NMR (500MHz, CDCl3) δ7.49–7.39(m,1H),6.34–6.28(m,1H),4.15(q,J=7.1Hz,2H),3.99(q,J=7.3Hz,2H ), 3.42–3.33(m,2H),2.53(s,3H),1.38(t,J=7.2Hz,3H),1.29(t,J=7.2Hz,3H),1.17(t,J=7.1Hz,3H). LCMS (Method A)m / z321.2[M+H] + , at 1.36min.
[0273] 29A 5-(5-((tert-Butyloxycarbonyl)(ethyl)amino)-3-fluoropyridin-2-yl)-1-ethyl-1H-pyrazole-4-carboxylic acid ethyl ester
[0274]
[0275] Intermediate 17C (130 mg, 0.380 mmol), tert-butyl ethylcarbamate (56 mg, 0.386 mmol) and CsCO3 (173 mg, 0.532 mmol) were placed in a vial. To the 4-thiazolinyl acetate (2mL) was added 4-nitropropane (2mL) and the reaction mixture was degassed with nitrogen. Pd2(dba)3(7mg, 7.64μmol) and Xantphos (11mg, 0.019mmol) were added, the reaction mixture was evacuated and purged with nitrogen (3×), then heated at 110°C overnight. Water (20mL), brine (10mL) and EtOAc (20mL) were added, separated, and the aqueous phase was extracted with EtOAc (2×10mL). The combined organic extracts were washed with brine (20mL), dried (MgSO4), and the solvent was removed under reduced pressure. The residue was purified by flash chromatography (0-50% EtOAc / isohexane) to obtain a light yellow gum (144mg, 88%). 1 H NMR (500MHz, CDCl3) δ8.55–8.50(m,1H),8.03(s,1H),7.59(d,J=10.3Hz,1H),4.19(q,J=7.1Hz,2H),4.14(q,J=7. 2Hz, 2H), 3.81 (q, J = 7.1Hz, 2H), 1.52 (s, 9H), 1.39 (t, J = 7.3Hz, 3H), 1.29 (t, J = 7.1Hz, 3H), 1.20 (t, J = 7.1Hz, 3H). LCMS (Method A): m / z 407.2[M+H] + , at 1.63min.
[0276] 30A Benzyl 3-[6-(Cyclopropylamino)-2-fluoropyridin-3-yl]-1-ethylpyrazole-4-carboxylate
[0277]
[0278] Cyclopropylamine (0.2mL, 2.91mmol) and DIPEA (0.2mL, 1.17mmol) were added to a solution of intermediate 19B (200mg, 0.58mmol) in DMSO (3mL), and the reaction was heated at 120°C for 30min by MWI. Water (40mL) and brine (40mL) were added and the mixture was extracted with EtOAc (3×40mL). The combined organic extracts were washed with brine (2×40mL), dried (MgSO4), and the solvent was removed under reduced pressure. Purification by flash chromatography (1:9 to 3:7 EtOAc:heptane) gave 3-[2-(cyclopropylamino)-6-fluoropyridin-3-yl]-1-ethylpyrazole-4-carboxylic acid benzyl ester as the first eluting regioisomer (colorless oil, 90mg, 41%), followed by intermediate 30A as the second eluting regioisomer (white oil, 95mg, 43%). Benzyl 3-[2-(Cyclopropylamino)-6-fluoropyridin-3-yl]-1-ethylpyrazole-4-carboxylate: 1 H NMR(400MHz, DMSO-d6)δ8.43(s,1H),7.60(dd,J=9.9,8.2Hz,1H),7.40–7.23(m,5H),6.48(dd,J=8.2,1.9Hz,1H) ,5.17(s,2H),4.19(q,J=7.2Hz,2H),1.41(t,J=7.3Hz,3H),0.73(td,J=6.8,4.6Hz,2H),0.58–0.37(m,2H).LRMS m / z:381.4[M+H] + Intermediate 30A: 1 H NMR (400MHz, DMSO-d6) δ8.51(s,1H),7.81(t,J=8.3Hz,1H),7.45–7.25(m,5H),7.02(s,1H),6.24(dd,J=8.0,2.9H z,1H),5.18(s,2H),4.21(q,J=7.2Hz,2H),1.41(t,J=7.3Hz,3H),0.67(td,J=6.9,4.7Hz,2H),0.43–0.35(m,2H). LRMS m / z:381.3[M+H] + .
[0279] The following intermediate compounds were prepared by procedures similar to those used for Intermediate 30A, wherein reaction times and / or temperatures were varied as indicated. Intermediates 30N, 300, 30P were prepared by conventional heating.
[0280]
[0281]
[0282]
[0283] 31A 5-(6-(Cyclopropylamino)-2-fluoropyridin-3-yl)-1-ethyl-1H-pyrazole-4-carboxylic acid
[0284]
[0285] LiOH (140 mg, 5.850 mmol) was added to a solution of intermediate 21C (231 mg, 0.730 mmol) in 1:1:1 MeOH:THF:water (3 mL). The reaction mixture was heated to 50 °C and stirred for 2 h. HCl (1M aq, 5 mL) and CH2Cl2 (10 mL) were added, the phases were separated, and the aqueous phase was extracted with 10% IPA / CHCl3 (5×10 mL). The combined organic phases were washed with brine (20 mL), dried (MgSO4), and the solvent was removed under reduced pressure to give a light yellow solid (195 mg, 93%). LCMS (Method A) m / z 291.2 [M+H] + , at 1.03min. 1 H NMR (500MHz, DMSO-d6) δ12.10(s,1H),7.90(s,1H),7.63–7.56(m,1H),7.54(d,J=2.6Hz,1H),6.56(d,J=8.3 Hz,1H),3.95–3.90(m,2H),2.59–2.54(m,1H),1.26(t,J=7.2Hz,3H),0.78–0.71(m,2H),0.51–0.45(m,2H).
[0286] The following intermediate compounds were prepared by the same general procedure.
[0287]
[0288]
[0289]
[0290] 32A 5-[6-(Cyclopropylamino)-2-fluoropyridin-3-yl]-1-(oxacyclohexane-4-yl)pyrazole-4-carboxylic acid
[0291]
[0292] A solution of intermediate 30J (56 mg, 0.15 mmol) and LiOH (1M aq., 1.2 mL, 1.2 mmol) in THF:MeOH (1:1; 6 mL) was heated at 55 °C for 4 h. The volatiles were removed under reduced pressure, and the residue was acidified to pH≈2 with HCl (1M aq.) and then extracted with EtOAc (3×10 mL). The combined organic extracts were washed with water and brine (10 mL each), dried (MgSO4), and the solvent was removed under reduced pressure to give a white solid (50 mg, 97%). 1 H NMR (400 MHz, DMSO-d6) δ 12.15 (s, 1H), 7.95 (s, 1H), 7.66–7.51 (m, 2H), 6.57 (d, J=8.2 Hz, 1H), 4.21–4.07 (m, 1H), 3.95–3.81 (m, 2H), 2.16–2.04 (m, 2H), 1.85–1.63 (m, 2H), 0.86–0.70 (m, 2H), 0.64–0.41 (m, 2H). LCMS (Method C), m / z 347 [M+H] + , at 1.60min.
[0293] The following intermediate compounds were prepared by the same general procedure.
[0294]
[0295]
[0296] 33A 3-[6-(Cyclopropylamino)-2-fluoropyridin-3-yl]-1-(oxacyclohexan-4-yl)pyrazole-4-carboxylic acid
[0297]
[0298] Palladium hydroxide on carbon (20 wt.% loading, 50% water; 34.9 mg, 0.22 mmol) was added to a solution of intermediate 35D (96 mg, 0.22 mmol) in EtOH (5 mL) in a pressure tube, and the vessel was purged sequentially with N (5×) and hydrogen (5×), then stirred under H at 40 psi for 70 min. The reaction was diluted with CH Cl (15 mL) and EtOH (5 mL), filtered through a glass microfiber pad, washed with CH Cl, and the solvent removed under reduced pressure to give a white solid (58 mg, 76%). 1HNMR (400MHz, DMSO-d6) δ12.14(s,1H),8.31(s,1H),7.60(dd,J=9.9,8.2Hz,1H),7.27(d,J=2.5Hz,1H),6.49(dd,J=8.2,1.9Hz,1H),4.44(dq ,J=10.4,5.4Hz,1H),3.96(dt,J=11.7,3.2Hz,2H),3.45(td,J=11.5,3.5Hz,3H),1.99(q,J=4.4Hz,4H),0.84–0.69(m,2H),0.57–0.38(m,2H). LRMS m / z:347.5[M+H] +
[0299] The following intermediate compounds were prepared by similar procedures to those described for Intermediate 33A.
[0300]
[0301]
[0302] 34A (6-(1-ethyl-4-(((S)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepine tert-Butyl (methyl)carbamoyl (methyl)-1H-pyrazol-5-yl)-5-fluoropyridin-3-yl (methyl)carbamate
[0303]
[0304] HATU (28 mg, 0.074 mmol), NEt3 (20 μL, 0.143 mmol), and then (S)-3-amino-5-phenyl-1H-benzo[e][1,4]diazepine -2(3H)-ketone (18 mg, 0.072 mmol) was added to a solution of intermediate 31H in DMF (1 mL), and the reaction was then stirred at rt for 16 h. Water (20 mL) was added, and the resulting precipitate was collected by filtration and washed with water. The precipitate was placed in CH2Cl2 (10 mL), passed through a phase separator containing saline (10 mL), and the solvent was removed under reduced pressure. Purification by flash chromatography [20-80% (10% MeOH / EtOAc) / isohexane] gave a white solid (35 mg, 81%). 1H NMR (500MHz, DMSO-d6) δ10.83(s,1H),8.96(d,J=7.8Hz,1H),8.27(s,1H),7.92(t,J=1.9H z,1H),7.62(ddd,J=8.6,7.2,1.6Hz,1H),7.55-7.48(m,1H),7.51-7.45(m,2H),7.48-7.41 (m,2H),7.32-7.26(m,2H),7.26-7.20(m,1H),6.80(dd,J=12.5,2.3Hz,1H),6.67(s,1H), 5.32(d,J=7.8Hz,1H), 3.99(q,J=7.2Hz,2H), 2.74(d,J=5.0Hz,3H), 1.25(t,J=7.2Hz,3H). LCMS (Method B)m / z 498.2[M+H] + , at 3.49min.
[0305] 34B N-ethyl-N-[6-[2-ethyl-4-[[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]carbamoyl]pyrazol-3-yl]-5-fluoropyridin-3-yl]carbamic acid tert-butyl ester
[0306]
[0307] Prepared by a procedure analogous to that described for Intermediate 34A. 1 HNMR(500MHz,DMSO-d6)δ10.83(s,1H),8.96(d,J=7.8Hz,1H),8.27(s,1H),7.93(t,J=1.9Hz,1H) ,7.62(ddd,J=8.6,7.1,1.6Hz,1H),7.55-7.48(m,1H),7.51-7.45(m,2H),7.48-7.41(m,2H),7.3 2-7.26 (m, 2H), 7.26-7.20 (m, 1H), 6.81 (dd, J = 12.6, 2.3 Hz, 1H), 6.65-6.59 (m, 1H), 5.32 (d, J = 7.8 Hz, 1H), 3.99 (q, J = 7.2 Hz, 2H), 3.15-3.06 (m, 2H), 1.25 (t, J = 7.2 Hz, 3H), 1.17 (t, J = 7.1 Hz, 3H). LCMS (Method B) m / z 512.3 [M+H] + , at 3.86min.
[0308] 35A 3-Ethoxy-1-ethylpyrazole-4-carboxylic acid ethyl ester
[0309]
[0310] K2CO3 (1.7 g, 12.3 mmol) and then EtI (1 mL, 12.4 mmol) were added to a solution of ethyl 3-oxo-1,2-dihydropyrazole-4-carboxylate (0.9 g, 5.76 mmol) in MeCN (20 mL) and the reaction was heated at 60 °C over the weekend. The reaction was cooled to rt and filtered, washing with MeCN (2×20 mL). The filtrate was concentrated under reduced pressure and purified by flash chromatography (0-50% MTBE / isohexane) to give a colorless oil (943 mg, 39%). Based on 1 H NMR δ pyrazole CH signal, the desired regioisomer was obtained as a 1:1 mixture with ethyl 5-ethoxy-1-ethylpyrazole-4-carboxylate. It was used without further purification. 1 H NMR (500 MHz, CDCl3) δ7.71 (s, 1H), 4.40–4.32 (m, 2H), 4.32–4.24 (m, 2H), 4.07–3.98 (m, 2H), 1.51–1.43 (m, 6H), 1.38–1.30 (m, 3H). LCMS (Method A) 213.5 [M+H] + , at 1.08min.
[0311] 36A 3-Ethoxy-1-ethyl-5-(2-fluorophenyl)pyrazole-4-carboxylic acid ethyl ester
[0312]
[0313] A solution of crude intermediate 35A (300 mg, 1.41 mmol, -50% purity) in anhydrous THF (4 mL) was degassed with N2. The solution was cooled to -78°C and LDA (2.0 M in THF; 0.9 mL, 1.8 mmol) and then zinc (II) chloride (2.0 M in 2-Me THF; 0.9 mL, 1.8 mmol) were added. The reaction mixture was warmed to rt and degassed with N2. 1-Bromo-2-fluorobenzene (0.19 mL, 1.74 mmol), Pd-170 (38 mg, 0.06 mmol) and XPhos (27 mg, 0.06 mmol) were added and the reaction mixture was evacuated, purged with N2 and then heated to 70°C for 5 h. 1M aq. HCl (30 mL) and EtOAc (30 mL) were added and the separated aqueous phase was extracted with EtOAc (2 x 10 mL). The combined organic phases were washed with brine (30 mL), dried (MgSO4) and concentrated under reduced pressure. Purification by flash chromatography (0-50% MTBE / isohexane) gave a yellow gum (193 mg, 45%). 1 HNMR (500MHz, CDCl3) δ7.50–7.42(m,1H),7.33–7.26(m,1H),7.26–7.20(m,1H),7.20–7.13(m,1H),4.38(q,J=7.0 Hz, 2H), 4.10–4.02 (m, 2H), 3.86–3.77 (m, 2H), 1.47 (t, J = 7.0Hz, 3H), 1.30 (t, J = 7.2Hz, 3H), 1.02 (t, J = 7.1Hz, 3H). LCMS(Method A)307.3[M+H] + , at 1.50min.
[0314] 37A 5-(5-chloro-2-fluoropyridin-3-yl)-1-ethylpyrazole-4-carboxylic acid ethyl ester
[0315]
[0316] A solution of intermediate 1A (1 g, 5.95 mmol) in anhydrous THF (10 mL) was degassed with N2. The solution was cooled to -78°C and LDA (2.0 M in THF; 3.4 mL, 6.8 mmol) and then zinc (II) chloride (2.0 M in 2-Me THF; 3.4 mL, 6.8 mmol) were added. The reaction was warmed to rt and degassed with N2. Pd(PPh3)4 (350 mg, 0.3 mmol) and 3-bromo-5-chloro-2-fluoropyridine (1.3 g, 6.18 mmol) were added and the reaction was evacuated and purged with N2 and then heated to 70°C overnight. 1M aq.HCl (50 mL) and EtOAc (50 mL) were added and the phases were separated. The aqueous phase was extracted with EtOAc (2 x 20 mL) and the combined organic phases were washed with brine (100 mL), dried (MgSO4) and concentrated under reduced pressure. Purification by flash chromatography (0-10% MTBE / isohexane) gave a yellow gum (1.2 g, 68%). 1 H NMR (500 MHz, CDCl3) δ 8.33–8.28 (m, 1H), 8.05 (s, 1H), 7.83–7.77 (m, 1H), 4.21–4.13 (m, 2H), 4.04–3.98 (m, 2H), 1.41 (t, J = 7.2 Hz, 3H), 1.19 (t, J = 7.1 Hz, 3H). LCMS (Method A) 298.3 [M+H] + , at 1.36min.
[0317] 38A(E)-2-(4-bromo-2-fluorobenzoyl)-3-(dimethylamino)prop-2-enoic acid ethyl ester
[0318]
[0319] DMF (0.07 mL, 0.91 mmol) and thionyl chloride (1.67 mL, 22.8 mmol) were added to a suspension of 4-bromo-2-fluorobenzoic acid (1 g, 4.57 mmol) in toluene (13 mL). The mixture was heated at 110 °C for 2 h, cooled to rt and concentrated under reduced pressure. The residue was dissolved in THF (5 mL), NEt3 (0.96 mL, 6.85 mmol) was added, and then ethyl-N,N-dimethylaminoacrylate (0.65 mL, 4.57 mmol) was added dropwise. The reaction was heated to reflux for 2 h, cooled to rt, and water and EtOAc (30 mL each) were added. The mixture was extracted with EtOAc (3×30 ml), and the combined organic phases were washed with water (30 mL), brine (30 mL), dried (Na2SO4) and concentrated under reduced pressure. Purification by flash chromatography (10-100% EtOAc / heptane) gave a yellow oil (1.16 g, 74%). 1 H NMR(700MHz,DMSO-d6)δ7.75(s,1H),7.53(dd,J=9.8,1.8Hz,1H),7.43(dd,J=8.2,1.8H z, 1H), 7.37 (d, J = 7.9Hz, 1H), 3.87 (q, J = 7.1Hz, 2H), 2.77 (s, 3H), 0.89 (t, J = 7.1Hz, 3H). LRMS m / z343.9 / 345.9[M+H] + .
[0320] The following intermediate compounds were prepared using the same general procedures described for Intermediate 38A.
[0321]
[0322]
[0323] 39A 5-(4-bromo-2-fluorophenyl)-1-(oxacyclohexan-4-yl)pyrazole-4-carboxylic acid ethyl ester
[0324]
[0325] Tetrahydro-2H-pyran-4-ylhydrazine hydrochloride (377 mg, 2.47 mmol) and NEt3 (0.34 mL, 2.47 mmol) were added to a cooled (0°C) suspension of intermediate 38A (850 mg, 2.47 mmol) in EtOH (25 mL). The mixture was warmed to rt over 10 min, stirred at rt for 16 h, and then heated at 40°C for 3 h. The reaction was concentrated under reduced pressure and purified by flash chromatography (10-50% EtOAc / heptane) to give a colorless oil (833 mg, 84%).1 H NMR (700MHz, DMSO-d6) δ8.05(s,1H),7.77(dd,J=9.3,1.9Hz,1H),7.59(dd,J=8.2,1.9Hz,1H),7.46(t,J=8.0Hz,1H),4.14–3.9 9(m,3H),3.92–3.83(m,2H),3.36–3.29(m,2H),2.14–2.02(m,2H),1.85–1.76(m,1H),1.68–1.58(m,1H),1.06(t,J=7.1Hz,3H). LRMS m / z:397.6 / 399.7[M+H] + .
[0326] 39B 5-(6-bromo-2-fluoropyridin-3-yl)-1-(oxacyclohexan-4-yl)pyrazole-4-carboxylic acid ethyl ester
[0327]
[0328] NEt3 (0.25mL, 1.8mmol) is added to a suspension of hydrochloric acid tetrahydro-2H-pyran-4-ylhydrazine (274mg, 1.80mmol) in CH2Cl2 (20mL), and the reaction is stirred for 2h at rt. The reaction is concentrated under reduced pressure and placed under N2. The intermediate 38B (620mg, 1.8mmol) added in EtOH (20mL) is stirred for 18h at rt, and then heated at 40°C for 3h. The mixture is concentrated under reduced pressure and purified by flash chromatography (10-50% EtOAc / heptane) to obtain an off-white solid (340mg, 48%). 1 H NMR (400MHz, DMSO-d6) δ8.13–8.04(m,2H),7.84(dd,J=7.8,1.1Hz,1H),4.31–4.17(m,1H),4.14–4.01(m,2H),3.94–3. 79(m,2H),3.40–3.34(m,2H),2.15–1.99(m,2H),1.84(d,J=12.7Hz,1H),1.66(d,J=12.7Hz,1H),1.07(t,J=7.1Hz,3H). LRMS m / z:398.1 / 400.0[M+H] + .
[0329] The following intermediate compounds were prepared by similar procedures to those described for Intermediate 39B.
[0330]
[0331] 39E 5-(2,6-difluoropyridin-3-yl)-1-(1-methylpiperidin-4-yl)pyrazole-4-carboxylic acid ethyl ester
[0332]
[0333] A solution of 4-hydrazino-1-methylpiperidine (450 mg, 3.48 mmol) and intermediate 38D (990 mg, 3.48 mmol) in EtOH (30 mL) was stirred at rt for 44 h. The reaction was concentrated under reduced pressure and purified by flash chromatography [0-60% (EtOH:CH2Cl2:NH4OH; 50:8:1) in CH2Cl2] to give a yellow oil (480 mg, 39%). 1 H NMR (400MHz, DMSO-d6) δ8.33(q,J=8.2Hz,1H),8.07(s,1H),7.39(dd,J=8.1,2.4Hz,1H),4.16–4.01(m,2H),3.96–3.78( m,1H),2.90–2.70(m,2H),2.13(s,3H),2.12–1.95(m,2H),1.94–1.78(m,3H),1.73–1.60(m,1H),1.05(t,J=7.1Hz,3H). LRMS m / z:351.3[M+H] + .
[0334] 39F 5-(4-bromo-2-fluorophenyl)-1-(1-methylpiperidin-4-yl)pyrazole-4-carboxylic acid ethyl ester
[0335]
[0336] Prepared by an analogous procedure to Intermediate 39E from Intermediate 38A and 4-hydrazino-1-methylpiperidine dihydrochloride. 1 HNMR(400MHz, DMSO-d6)δ8.08(s,1H),7.80(dd,J=9.3,1.9Hz,1H),7.61(dd,J=8.2,1.9Hz,1H),7.48(t,J=8.0Hz,1H), 4.16–3.94(m,3H),3.25–3.08(m,3H),2.32–2.15(m,2H),2.08–1.88(m,1H),1.88–1.73(m,1H),1.07(t,J=7.1Hz,3H). LRMS m / z:410.4 / 412.4[M+H] + .
[0337] 40A 5-(5-cyclopropyl-2-fluoropyridin-3-yl)-1-ethylpyrazole-4-carboxylic acid ethyl ester
[0338]
[0339] Pd-170 (20 mg, 0.030 mmol), K2CO3 (209 mg, 1.51 mmol) and potassium cyclopropyltrifluoroborate (90 mg, 0.61 mmol) were loaded into a reaction vessel. The vessel was evacuated, purged with N2, and then a solution of intermediate 37A (150 mg, 0.50 mmol) in THF: water (1: 1, 2 mL) was added. The reaction mixture was sprayed with N2 and then heated to 70 ° C overnight. Water (50 mL) and EtOAc (50 mL) were added, and the separated aqueous phase was extracted with EtOAc (2×20 mL). The combined organic phases were washed with brine (100 mL), dried (MgSO4) and concentrated under reduced pressure. A light yellow oil (98 mg, 61%) was obtained by flash chromatography (0-10% MTBE / isohexane). 1 H NMR (500MHz, CDCl3) δ8.14–8.10(m,1H),8.04(s,1H),7.42(dd,J=8.6,2.6Hz,1H),4.15(q,J=7.1Hz,2H),4.02– 3.95(m,2H),2.01–1.92(m,1H),1.39(t,J=7.2Hz,3H),1.18–1.15(m,3H),1.10–1.06(m,2H),0.75–0.72(m,2H). LCMS(Method A)304.3[M+H] + , at 1.37min.
[0340] 40B 5-(5-cyclopropyl-2-fluoropyridin-3-yl)-1-(oxacyclohexan-4-yl)pyrazole-4-carboxylic acid ethyl ester
[0341]
[0342] A solution of intermediate 39C (300 mg, 0.75 mmol) in toluene (3 mL) and water (0.3 mL) was degassed with N2 for 15 min. K2CO3 (312 mg, 2.26 mmol) and potassium cyclopropyltrifluoroborate (167 mg, 1.13 mmol) were added, followed by RuPhos (35.1 mg, 0.08 mmol) and Pd(OAc)2 (10.2 mg, 0.05 mmol). The vial was sealed and heated at 100°C for 2 h, then at 80°C overnight. The mixture was sparged with N2 for 15 min, additional Pd(OAc)2 (5.1 mg, 0.02 mmol) and RuPhos (17.6 mg, 0.04 mmol) were added, and the reaction was heated at 100°C for 4 h. After cooling to rt, the reaction was diluted with CH2Cl2 (20 mL) and filtered through a pad of Celite, washed with CH2Cl2 (2×15 mL). The filtrate was dried (Na2SO4) and concentrated under reduced pressure. Purification by flash chromatography (10-50% EtOAc / heptane) gave a colorless oil (85 mg, 31%). LRMS m / z: 360.3 [M+H] + .TLC R f =0.23 (2:1 EtOAc / heptane).
[0343] 40C 5-(2-Fluoro-4-prop-1-en-2-ylphenyl)-1-(oxacyclohexan-4-yl)pyrazole-4-carboxylic acid ethyl ester
[0344]
[0345] A solution of intermediate 39A (120 mg, 0.3 mmol) in toluene (1.5 mL) and water (0.1 mL) was degassed with N2 for 15 min. Potassium trifluoro(prop-1-en-2-yl)borate (67 mg, 0.45 mmol) was added, followed by K2CO3 (125 mg, 0.91 mmol), RuPhos (14.1 mg, 0.03 mmol) and Pd(OAc)2 (4.1 mg, 0.02 mmol), and the reaction was heated at 100 °C for 6 h. After cooling to rt, the mixture was diluted with CH2Cl2 (10 mL) and filtered through a pad of Celite, washed with CH2Cl2 (3×10 mL). The filtrate was concentrated under reduced pressure and purified by flash chromatography (10-50% EtOAc / heptane) to give a yellow solid (92 mg, 85%). LRMS m / z: 359.2 [M+H] + .TLC R f =0.63 (1:1 EtOAc / heptane).
[0346] The following intermediate compounds were prepared by similar procedures to that described for Intermediate 40C.
[0347]
[0348] 41A 5-(2-fluoro-4-propan-2-ylphenyl)-1-(oxacyclohexan-4-yl)pyrazole-4-carboxylic acid ethyl ester
[0349]
[0350] A solution of intermediate 40C (92 mg, 0.26 mmol) in EtOH (10 mL) in a pressure tube was evacuated and filled with N2 (3×). Pd / C (10% wt. loading; 27.3 mg, 0.26 mmol) was added, and the reaction was stirred at rt under H2 (20 psi) for 2 h. The mixture was filtered, washed with EtOH (2×10 mL) and CH2Cl2 (2×10 mL), and the filtrate was concentrated under reduced pressure to give a colorless oil (70 mg, 76%). LRMS m / z: 361.1 [M+H] + .TLC R f = 0.63 (1:1 EtOAc / heptane).
[0351] The following intermediate compounds were prepared by similar procedures to those described for Intermediate 41A.
[0352]
[0353] Example
[0354] 1.1-Ethyl-5-[2-fluoro-6-(methylamino)pyridin-3-yl]-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide
[0355]
[0356] NEt3 (15 μL, 0.108 mmol), HATU (22 mg, 0.058 mmol) and then (S)-3-amino-5-phenyl-1H-benzo[e][1,4]diazepine -2(3H)-ketone (14 mg, 0.056 mmol) was added to a solution of intermediate 31E (14 mg, 0.056 mmol) in DMF (1 mL). The reaction mixture was stirred overnight at rt. Water (20 mL) was added, and the precipitate was collected by filtration and washed with water. The precipitate was placed in CH2Cl2 (10 mL), and the solvent was removed under reduced pressure by a phase separator containing saline (10 mL). Purification by flash chromatography [0-60% (10% MeOH / EtOAc) / isohexane] gave a white solid (21 mg, 76%). 1 H NMR(500MHz,DMSO-d6)δ10.83(s,1H),8.82(d,J=8.0Hz,1H),8.37(s,1H),7 .62(ddd,J=8.6,7.2,1.6Hz,1H),7.56–7.47(m,3H),7.47–7.41(m,3H),7.32 –7.26(m,2H),7.27–7.19(m,2H),6.38(dd,J=8.2,1.8Hz,1H),5.34(d,J=7.9 Hz, 1H), 3.92 (q, J = 7.2Hz, 2H), 2.76 (d, J = 4.8Hz, 3H), 1.26 (t, J = 7.2Hz, 3H). LCMS (Method B) m / z 498.2 [M+H] + , at 3.52min.
[0357] The compound of Example 1 was reacted with (3S)-3-amino-5-phenyl-1,3-dihydro-1,4-benzodiazepine by the amide coupling procedure described for the compound of Example 1. -2-one or (3S)-3-amino-9-fluoro-5-phenyl-1,3-dihydro-1,4-benzodiazepine The following compounds of the present invention were prepared by using the following oxazolidinones:
[0358] The compound was prepared as in Example 1 by amide coupling.
[0359]
[0360]
[0361]
[0362]
[0363]
[0364]
[0365]
[0366]
[0367]
[0368]
[0369]
[0370]
[0371]
[0372] 38.1-Ethyl-5-(3-fluoro-5-(methylamino)pyridin-2-yl)-N-((S)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepine -3-yl)-1H-pyrazole-4-carboxamide
[0373]
[0374] HCl (4.0 M, in 50 μL, 0.200 mmol) was added to a solution of intermediate 34A (30 mg, 0.050 mmol) in CH2Cl2 (1 mL) and stirred at rt. After 1 h, further HCl (4.0 M in dihydrogen sulfoxide) was added. The product was concentrated to 4% by volume with 1% paraformaldehyde (1% paraformaldehyde; 200 μL, 0.800 mmol) and the reaction was stirred at rt over the weekend. The reaction was partitioned between CH2Cl2 (10 mL) and saturated aq. NaHCO3 (10 mL), separated and the aqueous phase extracted with CH2Cl2 (2×10 mL). The combined organic extracts were washed with brine (20 mL), dried (MgSO4) and the solvent removed under reduced pressure. Purification by flash chromatography [50-100% (10% MeOH / EtOAc) / isohexane] gave a white solid (14 mg, 56%). 1H NMR (500MHz, DMSO-d6) δ10.83(s,1H),8.96(d,J=7.8Hz,1H),8.27(s,1H),7.92(t,J=1.9H z,1H),7.62(ddd,J=8.6,7.2,1.6Hz,1H),7.55-7.48(m,1H),7.51-7.45(m,2H),7.48-7.41 (m,2H),7.32-7.26(m,2H),7.26-7.20(m,1H),6.80(dd,J=12.5,2.3Hz,1H),6.67(s,1H), 5.32(d,J=7.8Hz,1H), 3.99(q,J=7.2Hz,2H), 2.74(d,J=5.0Hz,3H), 1.25(t,J=7.2Hz,3H). LCMS (Method B)m / z 498.2[M+H] + , at 3.49min.
[0375] 39.1-Ethyl-5-[5-(ethylamino)-3-fluoropyridin-2-yl]-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide
[0376]
[0377] Prepared by a procedure analogous to that described for Example 38 compound from intermediate 34B. 1 H NMR(500MHz,DMSO-d6)δ10.83(s,1H),8.96(d,J=7.8Hz,1H),8.27(s,1H),7.93(t,J=1.9Hz,1H) ,7.62(ddd,J=8.6,7.1,1.6Hz,1H),7.55-7.48(m,1H),7.51-7.45(m,2H),7.48-7.41(m,2H),7.3 2-7.26 (m, 2H), 7.26-7.20 (m, 1H), 6.81 (dd, J = 12.6, 2.3 Hz, 1H), 6.65-6.59 (m, 1H), 5.32 (d, J = 7.8 Hz, 1H), 3.99 (q, J = 7.2 Hz, 2H), 3.15-3.06 (m, 2H), 1.25 (t, J = 7.2 Hz, 3H), 1.17 (t, J = 7.1 Hz, 3H). LCMS (Method B) m / z 512.3 [M+H] + , at 3.86min.
[0378] 56.5-[6-(Cyclopropylamino)pyridin-3-yl]-1-(oxacyclohexane-4-yl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide
[0379]
[0380] A solution of intermediate 30O (296 mg, 0.83 mmol) and LiOH (1 M.aq., 6.64 mL, 6.64 mmol) in THF:MeOH (16 mL) was heated at 55 °C for 3 h. The reaction was cooled to rt, acidified with 1 M aq.HCl (pH≈2) and the solvent removed under reduced pressure. The residue was suspended in DMF (6 mL), then DIPEA (0.23 mL, 1.33 mmol) and HATU (278 mg, 0.732 mmol) were added and the reaction was stirred at rt for 10 min. (3S)-3-amino-9-fluoro-5-phenyl-1,3-dihydro-1,4-benzodiazepine was added. -2-ketone (179 mg, 0.67 mmol) and the reaction was stirred at rt for 4 h. The mixture was poured into water (50 mL) and the resulting precipitate was collected by filtration and washed with water (2×15 mL). The precipitate was dissolved in CH2Cl2 (50 mL), dried (Na2SO4), concentrated under reduced pressure and purified by flash chromatography (EtOAc) to give a white solid (105 mg, 27%). 1 HNMR(600MHz,DMSO-d6)δ10.79(s,1H),8.66(d,J=7.8Hz,1H),8.33(s,1H),8.02–7 .93(m,1H),7.60–7.49(m,4H),7.51–7.41(m,3H),7.32–7.25(m,1H),7.17–7.09(m ,2H),6.65(d,J=8.6Hz,1H),5.38(d,J=7.7Hz,1H),4.20–4.11(m,1H),3.95–3.85( m,2H),2.18–2.06(m,2H),1.81–1.72(m,2H),0.74–0.62(m,2H),0.48–0.33(m,2H). LRMS m / z:580.1[M+H] +
[0381] The following compounds of the present invention were prepared by procedures similar to those described for the compound of Example 56.
[0382] The compound was prepared as in Example 56 by amide coupling.
[0383]
[0384]
[0385] Example 60: In vitro efficacy
[0386] Compounds were subjected to RSV plaque reduction assays according to the following protocol.
[0387] Plaque reduction assay.
[0388] Make Hep-G2 cell (ECACC, 85011430) go down to posterity in flask and be seeded in the DMEM containing antibiotic and supplementing 10%FBS in 24-well plates.During inoculation and subsequent cultivation, cell is cultivated in the DMEM containing 2%FBS.100 plaque forming units / wells of RSV (RSV A2 ECACC, 0709161v) are mixed with eight serial dilutions of compound.Subsequently, 100 μ L virus / compound mixtures are added in the Hep-G2 cell monolayer that converges.Cell and virus / compound mixture are cultivated 2h at 37 ℃ in humidifying 5%CO2 incubator, then remove inoculum and add the covering material (DMEM containing 2%FBS and 0.8%CMC) of 1mL containing compound dilution.Cell is cultivated 2 days at 37 ℃ in humidifying 5%CO2 incubator.
[0389] Cells were washed with PBS for 3 min before adding 75 / 25% v / v EtOH / MeOH. Fixative was removed and the plate was washed with PBS. The primary antibody titrated in advance was added to 200 μL PBS / 2% milk powder, and the plate was cultivated for 90 min at 37 ° C. The plate was washed 3 times with PBS / 0.05% Tween20, then rabbit anti-goat horseradish peroxidase was added in 200 μL PBS / 2% milk powder, and cultivated for 1 h at 37 ° C. After three washing steps using PBS / 0.05% Tween20, 200 μL of ready-to-use TrueBlue was added and the plate was cultivated for 10-15 min at rt, then washed with water. After removing the water, the plate was air-dried in the dark.
[0390] The plates were scanned and analyzed using an Immunospot S6 Macro analyzer equipped with BioSpot analysis software to count immunostained plaques (virospots). Plaque counts were used to calculate the % infection relative to the mean plaque counts in RSV virus control wells. EC values were calculated by interpolation of inhibition curves fitted with a 4-parameter nonlinear regression with variable slope in Dotmatics. 50Values were calculated as 50% signal reduction. 50 and cytotoxic CC 50 Values are the means of at least two experiments, and numbers are rounded to integer units.
[0391] result
[0392]
[0393]
[0394]
[0395] Example 61: In vitro pharmacokinetics
[0396] Compounds were subjected to the following assays to study liver microsomal stability, permeability, and plasma protein binding.
[0397] Microsome cultivation: experimental procedure
[0398] The pooled liver microsomes were purchased from a reputable commercial supplier and stored at -80°C before use. Microsomes (final protein concentration 0.5 mg / mL), 0.1 M phosphate buffer pH 7.4 and test compounds (final substrate concentration 1 μM; final DMSO concentration 0.25%) were pre-incubated at 37°C, and then NADPH (final concentration 1 mM) was added to start the reaction. The final incubation volume was 50 μL. Control incubations were included for each tested compound, in which 0.1 M phosphate buffer pH 7.4 was added instead of NADPH (NADPH-). Two control compounds were included for each species. All incubations were performed separately for each test compound. Each compound was incubated for 0, 5, 15, 30 and 45 min. The control (NADPH-) was only incubated for 45 min. The reaction was stopped by transferring the incubation to acetonitrile at a ratio of 1:3 at the appropriate time point. The termination plate was centrifuged at 3,000 rpm for 20 min at 4°C to precipitate protein. After protein precipitation, sample supernatants were combined in boxes of up to 4 compounds, internal standards were added, and samples were analyzed by LC-MS / MS. The gradient of the line was determined based on the plot of ln peak area ratio (compound peak area / internal standard peak area) vs. time. Subsequently, the half-life (t 1 / 2 ) and intrinsic clearance (CL int Compounds with low clearance (>80% retention at 45 min) under the assay conditions were analyzed with t 1 / 2 >140min means.
[0399] result
[0400]
[0401]
[0402] Hepatocyte culture: experimental procedures
[0403] Cryopreserved pooled hepatocytes were purchased from a reputable commercial supplier and stored in liquid nitrogen before use. Williams E medium supplemented with 2 mM L-glutamine and 25 mM HEPES and test compounds (final substrate concentration 3 mM; final DMSO concentration 0.25%) were pre-incubated at 37°C, and then cryopreserved hepatocyte suspension (final cell density of 0.5 x 10 in Williams E medium supplemented with 2 mM L-glutamine and 25 mM HEPES) was added. 6 The reaction was started with 500 μL of culture medium (viable cells / mL). The final incubation volume was 500 μL. Each species included two control compounds, as well as appropriate vehicle controls. The reaction was stopped by transferring 50 μL of the culture to 100 μL of acetonitrile containing the internal standard at the appropriate time point. Samples were taken out at 6 time points (0, 5, 15, 30, 45 and 60 min) over a 60 min experimental period. The termination plate was centrifuged at 2500 rpm for 30 min at 4 ° C to precipitate the protein. After protein precipitation, the sample supernatants were combined in boxes of up to 4 compounds and analyzed using universal LC-MS / MS conditions. The gradient of the line was determined based on the plotting of the ln peak area ratio (compound peak area / internal standard peak area) vs time. Subsequently, the half-life (t1 / 2) and intrinsic clearance (CL) were calculated. int Compounds with low clearance (>80% retention at 60 min) under the assay conditions were analyzed with t 1 / 2 >186min means.
[0404] result
[0405]
[0406]
[0407] Example 62: In vivo pharmacokinetics
[0408] The pharmacokinetics of the compound were studied in vivo in rats at doses of 1 mg / kg (IV) and 10 mg / kg (PO).
[0409] Pharmacokinetics in rats
[0410] method
[0411] Male rats (Sprague Dawley) surgically prepared with jugular vein cannulated were treated with test compounds by intravenous administration (IV; n=3; 1 mg / kg) or oral administration (PO; n=3; 10 mg / kg). Compounds were formulated as solutions in 40:60 dimethylacetamide: saline (IV administration), suspensions in 1% methylcellulose (viscosity: 15 cP), 0.1% Tween 80 in water (PO administration: Example 3), solutions in 10% DMSO / 10% Cremaphor / 80% water (PO administration: Examples 4, 11, 21, 23, 25, 26, 32), or solutions in 10% DMSO / 20% Cremaphor / 70% water (PO administration: Examples 19, 20, 22, 24, 30). Animals were observed for any overt clinical signs or symptoms. Serial blood samples were collected by cannula at 0.02, 0.08, 0.25, 0.5, 1, 2, 4, 6, 8 and 24 h after IV administration of the compound, and at 0.08, 0.25, 0.5, 1, 2, 4, 6, 8 and 24 h after oral administration of the compound, and plasma was prepared by centrifugation and immediately stored at -80 ° C. The samples were then thawed, prepared for analysis by precipitating proteins with acetonitrile, and analyzed by tandem LCMS using electrospray ionization with a matrix-matched calibration curve. PK parameters were calculated from the obtained data.
[0412] result
[0413]
[0414]
[0415]
[0416] Canine Pharmacokinetics
[0417] The pharmacokinetics of compounds of the invention were studied in vivo in dogs.
[0418] method
[0419] Male beagle dogs were treated with test compounds by intravenous administration (n=2; 0.5 mg / kg) or oral administration (n=2; 3 mg / kg or 4 mg / kg). The compounds were formulated as solutions in 20% dimethylacetamide / 80% (2-hydroxypropyl)-β-cyclodextrin (20% w / v) (IV administration) or in 10% dimethylacetamide / 90% (2-hydroxypropyl)-β-cyclodextrin (20% w / v) (PO administration). Animals were observed for any overt clinical signs or symptoms. Serial blood samples were collected from the jugular vein at 0.03, 0.08, 0.25, 0.5, 1, 2, 4, 6, 8 and 24 h after IV administration of the compound, and at 0.08, 0.25, 0.5, 1, 2, 4, 6, 8 and 24 h after oral administration of the compound, and plasma was prepared by centrifugation and immediately stored at -80°C. The samples were then thawed, prepared for analysis by precipitating the proteins with acetonitrile, and analyzed by tandem LCMS using electrospray ionization with a matrix-matched calibration curve. PK parameters were calculated from the data obtained.
[0420] result
[0421] Example 4 21 22 24 Dosage: IV / PO (mg / kg) 0.5 / 4 0.5 / 3 0.5 / 4 0.5 / 4 <![CDATA[PO AUC 最后 (hr*ng / mL)]]> 2679 3608 6052 2302 Cl(mL / min / kg) 10.3 4.2 4.1 6.5 <![CDATA[V d (L / kg)]]> 0.79 1.3 1.4 0.86 <![CDATA[C 最大 (ng / mL)]]> 780 500 692 450 C 8h(ng / mL) 56.1 146 281 67 <![CDATA[IV t 1 / 2 (h)]]> 1 7.6 4.9 1.5 <![CDATA[PO t 1 / 2 (h)]]> 2.3 5.6 6.8 2.4 F(%) 41.5% 33.6% 40.1% 22.7%
[0422] Example 63: Aqueous Formulation
[0423] The compound of Example 1 was formulated as a solution in 30% w / v Captisol (ie, sulfobutyl ether-β-cyclodextrin) at pH 4 according to the following procedure.
[0424] The vehicle 30% w / v Captisol (ie sulfobutyl ether-β-cyclodextrin) was prepared by weighing the required amount of Captisol into a suitable container, adding approximately 80% of the final volume of water and stirring magnetically until a solution was formed. The vehicle was then made up to volume with water.
[0425] An aqueous solution of the compound of Example 1 was prepared by weighing 175 mg of the compound into a suitable container and adding approximately 80% of the required volume of carrier. The pH was adjusted to pH 2 using aqueous hydrochloric acid and the resulting mixture was stirred magnetically until a solution was formed. The formulation was then made up to volume with carrier and the pH was adjusted to pH 4 using aqueous sodium hydroxide.
[0426] Example 64: Tablet Composition
[0427] Tablets, each weighing 0.15 g and containing 25 mg of a compound of the invention, are manufactured as follows:
[0428] Composition of 10,000 tablets
[0429] Compound of the present invention (250 g)
[0430] Lactose (800g)
[0431] Corn starch (415g)
[0432] Talc (30g)
[0433] Magnesium stearate (5g)
[0434] The compound of the present invention, lactose and half of corn starch are mixed. The mixture is then forced to pass through a sieve with a mesh size of 0.5 mm. Corn starch (10 g) is suspended in warm water (90 mL). The resulting paste is used to granulate the powder. The particles are dried and broken into small pieces on a sieve with a mesh size of 1.4 mm. The remaining amount of starch, talc and magnesium are added, carefully mixed and processed into tablets.
[0435] Example 65: Injectable Formulation
[0436]
[0437] The compound of the invention was dissolved in mostly water (35°C-40°C) and the pH was adjusted to 4.0 to 7.0 with hydrochloric acid or sodium hydroxide as appropriate. The batch was then made up to volume with water and filtered through a sterile microporous filter into a sterile 10 mL amber glass vial (Type 1) and sealed with a sterile cap and seal.
[0438] Example 66: Intramuscular injection
[0439]
[0440] The compound of the present invention was dissolved in glycofurol. Benzyl alcohol was then added and dissolved, and water was added to 3 mL. The mixture was then filtered through a sterile microporous filter and sealed in a sterile 3 mL glass vial (Type 1).
[0441] Example 67: Syrup Formulation
[0442] #imgpt227#
[0443] The compound of the invention is dissolved in a mixture of glycerol and mostly purified water. Then the sodium benzoate aqueous solution is added to the solution, followed by the sorbitol solution and finally the flavoring. Make up to volume with purified water and mix thoroughly.
Claims
1. A compound selected from: 1-Ethyl-5-[2-fluoro-6-(methylamino)pyridin-3-yl]-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide; 1-Ethyl-5-[6-(ethylamino)-2-fluoropyridin-3-yl]-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide; 1-Ethyl-5-[2-fluoro-6-(propan-2-ylamino)pyridin-3-yl]-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide; 1-Ethyl-5-[2-fluoro-6-(cyclopropylamino)pyridin-3-yl]-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide; 5-[6-(Cyclobutylamino)-2-fluoropyridin-3-yl]-1-ethyl-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide; 1-Ethyl-5-[2-fluoro-6-[(1-methylcyclopropyl)amino]pyridin-3-yl]-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide; 5-[5-(Cyclopropylamino)-3-fluoropyridin-2-yl]-1-ethyl-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide; 1-Ethyl-5-[3-fluoro-5-(propan-2-ylamino)pyridin-2-yl]-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide; 1-Ethyl-5-[2-fluoro-4-(propan-2-ylamino)phenyl]-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide; 1-ethyl-5-[6-(ethylamino)-2-fluoropyridin-3-yl]-3-methyl-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide; 5-[6-(Cyclopropylamino)-2-fluoropyridin-3-yl]-1-ethyl-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide; 5-[5-(Cyclopropylamino)-3-fluoropyridin-2-yl]-1-ethyl-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide; 1-Ethyl-5-[5-(ethylamino)-3-fluoropyridin-2-yl]-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide; 1-Cyclopropyl-5-[6-(ethylamino)-2-fluoropyridin-3-yl]-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide; 1-Cyclopropyl-5-[6-(cyclopropylamino)-2-fluoropyridin-3-yl]-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide; 5-[6-(Cyclopropylamino)-2-fluoropyridin-3-yl]-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-1-propan-2-ylpyrazole-4-carboxamide; 1-Ethyl-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-5-[3-fluoro-5-(propan-2-ylamino)pyridin-2-yl]pyrazole-4-carboxamide; 5-[6-(Cyclopropylamino)-2-fluoropyridin-3-yl]-1-(oxetan-3-yl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide; 5-[6-(Cyclopropylamino)-2-fluoropyridin-3-yl]-1-(oxetan-3-yl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide; 5-[6-(Cyclopropylamino)-2-fluoropyridin-3-yl]-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-1-(oxacyclohexan-4-yl)pyrazole-4-carboxamide; 5-[6-(Cyclopropylamino)-2-fluoropyridin-3-yl]-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-1-(oxacyclohexan-4-yl)pyrazole-4-carboxamide; N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-5-[2-fluoro-6-(propan-2-ylamino)pyridin-3-yl]-1-(oxacyclohexan-4-yl)pyrazole-4-carboxamide; 5-[2-Fluoro-6-(propan-2-ylamino)pyridin-3-yl]-1-(oxacyclohexan-4-yl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide; 5-[6-(Ethylamino)-2-fluoropyridin-3-yl]-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-1-(oxacyclohexan-4-yl)pyrazole-4-carboxamide; 3-[6-(Cyclopropylamino)-2-fluoropyridin-3-yl]-1-ethyl-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide; 3-[6-(Cyclopropylamino)-2-fluoropyridin-3-yl]-1-ethyl-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide; 1-Ethyl-3-[2-fluoro-6-(propylamino)pyridin-3-yl]-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide; 1-Ethyl-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-3-[2-fluoro-6-(propylamino)pyridin-3-yl]pyrazole-4-carboxamide; 1-tert-Butyl-3-[6-(cyclopropylamino)-2-fluoropyridin-3-yl]-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide; 1-tert-Butyl-3-[6-(cyclopropylamino)-2-fluoropyridin-3-yl]-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide; 3-[6-(Cyclopropylamino)-2-fluoropyridin-3-yl]-1-(oxacyclohexan-4-yl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide; 3-[6-(Cyclopropylamino)-2-fluoropyridin-3-yl]-N-[(3S)-9-fluoro-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepine -3-yl]-1-(oxacyclohexan-4-yl)-1H-pyrazole-4-carboxamide; 3-[6-(Cyclopropylamino)-2-fluoropyridin-3-yl]-N-[(3S)-9-fluoro-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepine -3-yl]-1-(2,2,2-trifluoroethyl)-1H-pyrazole-4-carboxamide; (3-[6-(Cyclopropylamino)-2-fluoropyridin-3-yl]-1-(4,4-difluorocyclohexyl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide; 3-[6-(Cyclopropylamino)-2-fluoropyridin-3-yl]-1-(4,4-difluorocyclohexyl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide; 3-[6-(Cyclopropylamino)-2-fluoropyridin-3-yl]-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-1-(oxetan-3-yl)pyrazole-4-carboxamide; 3-[6-(Cyclopropylamino)-2-fluoropyridin-3-yl]-1-(oxetan-3-yl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide; 1-Ethyl-5-(3-fluoro-5-(methylamino)pyridin-2-yl)-N-((S)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepine -3-yl)-1H-pyrazole-4-carboxamide; 1-Ethyl-5-[5-(ethylamino)-3-fluoropyridin-2-yl]-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide; 5-[6-(Ethylamino)-2-fluoropyridin-3-yl]-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-1-(oxetan-3-yl)pyrazole-4-carboxamide; N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-5-[2-fluoro-6-(propan-2-ylamino)pyridin-3-yl]-1-(oxetan-3-yl)pyrazole-4-carboxamide; 5-[6-(Ethylamino)-2-fluoropyridin-3-yl]-1-(oxacyclohexan-4-yl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide; 5-(4-cyclopropyl-2-fluorophenyl)-1-(oxacyclohexan-4-yl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide; 5-(4-cyclopropyl-2-fluorophenyl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-1-(oxacyclohexan-4-yl)pyrazole-4-carboxamide; 5-(2-Fluoro-4-propan-2-ylphenyl)-1-(oxacyclohexan-4-yl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide; 5-(4-ethyl-2-fluorophenyl)-1-(oxacyclohexan-4-yl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide; 5-(4-ethyl-2-fluorophenyl)-1-(oxacyclohexan-4-yl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide; 5-(5-cyclopropyl-2-fluoropyridin-3-yl)-1-ethyl-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide; 5-(6-cyclopropyl-2-fluoropyridin-3-yl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-1-(oxacyclohexan-4-yl)pyrazole-4-carboxamide; 5-(5-cyclopropyl-2-fluoropyridin-3-yl)-1-(oxacyclohexan-4-yl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide; 5-(5-cyclopropyl-2-fluoropyridin-3-yl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-1-(oxacyclohexan-4-yl)pyrazole-4-carboxamide; 5-(6-ethyl-2-fluoropyridin-3-yl)-1-(oxacyclohexan-4-yl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide; 5-(6-ethyl-2-fluoropyridin-3-yl)-1-(oxacyclohexan-4-yl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide; 3-Ethoxy-1-ethyl-5-(2-fluorophenyl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide; 3-Ethoxy-1-ethyl-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-5-(2-fluorophenyl)pyrazole-4-carboxamide; 5-[6-(Cyclopropylamino)pyridin-3-yl]-1-(oxacyclohexan-4-yl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide; 5-[6-(Cyclopropylamino)-2-fluoropyridin-3-yl]-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-1-(1-methylpiperidin-4-yl)pyrazole-4-carboxamide; 1-(Oxan-4-yl)-5-[6-(propan-2-ylamino)pyridin-3-yl]-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide; 5-(4-ethyl-2-fluorophenyl)-1-(1-methylpiperidin-4-yl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazole-4-carboxamide; and pharmaceutically acceptable salts thereof.
2. A pharmaceutical composition comprising a compound as defined in claim 1 and a pharmaceutically acceptable carrier or diluent.
3. Use of a compound as defined in claim 1 in the preparation of a medicament for treating or preventing RSV infection.
4. A process for producing a pharmaceutically acceptable salt as defined in claim 1, said process comprising treating a benzodiazepine of formula (I) as defined in claim 1 with a suitable acid in a suitable solvent. derivative.
5. The method of claim 4, wherein the acid is selected from the group consisting of hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, benzenesulfonic acid, formic acid, acetic acid, trifluoroacetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, ethanesulfonic acid, aspartic acid and glutamic acid.
